

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07C 317/44, A61K 31/18</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/10136</p> <p>(43) International Publication Date: 11 May 1994 (11.05.94)</p>
<p>(21) International Application Number: PCT/US93/10461</p> <p>(22) International Filing Date: 29 October 1993 (29.10.93)</p> <p>(30) Priority data: 07/969,612 30 October 1992 (30.10.92) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 07/969,612 (CON) Filed on 30 October 1992 (30.10.92)</p> <p>(71) Applicants (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Department, P.O. Box 5110, Chicago, IL 60680-5110 (US). THE MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard, St. Louis, MN 63166 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): VAZQUEZ, Michael, L. [US/US]; 233 Saratoga Court, Gurnee, IL 60031 (US). MUELLER, Richard, A. [US/US]; 562 Stonegate Terrace, Glencoe, IL 60022 (US). TALLEY, John, J. [US/US]; 1510 Amisk Court, Chesterfield, MO 63017 (US). GETMAN, Daniel, P. [US/US]; 66 Sunnyhill Court, Chesterfield, MO 63017 (US). DECRESCENZO, Gary, A. [US/US]; 536 Schrader Farm Drive, St. Peters, MO 63376 (US). SUN, Eric, T. [US/US]; 7614 Palmilla Drive, Apartment 58, San Diego, CA 92122 (US).</p>		<p>(74) Agents: UNGEMACH, Frank, S. et al.; G.D. Searle & Co., Corporate Patent Department, P.O. Box 5110, Chicago, IL 60680-5110 (US).</p> <p>(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACIDS USEFUL AS RETROVIRAL PROTEASE INHIBITORS</p> <div style="text-align: center; margin: 20px 0;"> <p style="text-align: right;">(I)</p> </div> <p>(57) Abstract</p> <p>Sulphonylalkanoylamino hydroxyamino sulphamic acid compounds represented by formula (I), or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein R, R¹, R²⁰, R²¹, R², R³, R⁴, R⁵, R⁶, x, t, and Y are as defined in the description, are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	CN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACIDS
USEFUL AS RETROVIRAL PROTEASE INHIBITORS

BACKGROUND OF THE INVENTION

5

1. Field of the Invention

The present invention relates to retroviral protease inhibitors and, more particularly, relates to novel compounds and a composition and method for
10 inhibiting retroviral proteases. This invention, in particular, relates to sulfamic acid-containing hydroxyethylamine protease inhibitor compounds, a composition and method for inhibiting retroviral proteases such as human immunodeficiency virus (HIV)
15 protease and for treating a retroviral infection, e.g., an HIV infection. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

20 2. Related Art

During the replication cycle of retroviruses, gag and gag-pol gene products are translated as proteins. These proteins are subsequently processed by a virally encoded protease (or proteinase) to yield viral enzymes
25 and structural proteins of the virus core. Most commonly, the gag precursor proteins are processed into the core proteins and the pol precursor proteins are processed into the viral enzymes, e.g., reverse transcriptase and retroviral protease. It has been shown
30 that correct processing of the precursor proteins by the retroviral protease is necessary for assembly of infectious virions. For example, it has been shown that frameshift mutations in the protease region of the pol gene of HIV prevents processing of the gag precursor
35 protein. It has also been shown through site-directed mutagenesis of an aspartic acid residue in the HIV

protease that processing of the gag precursor protein is prevented. Thus, attempts have been made to inhibit viral replication by inhibiting the action of retroviral proteases.

5

Retroviral protease inhibition may involve a transition-state mimetic whereby the retroviral protease is exposed to a mimetic compound which binds to the enzyme in competition with the gag and gag-pol proteins to thereby inhibit replication of structural proteins and, more importantly, the retroviral protease itself. In this manner, retroviral replication proteases can be effectively inhibited.

15

Several classes of compounds have been proposed, particularly for inhibition of proteases, such as for inhibition of HIV protease. Such compounds include hydroxyethylamine isosteres and reduced amide isosteres. See, for example, EP O 346 847; EP O 342,541; Roberts et al, "Rational Design of Peptide-Based Proteinase Inhibitors, "Science, 248, 358 (1990); and Erickson et al, "Design Activity, and 2.8Å Crystal Structure of a C₂ Symmetric Inhibitor Complexed to HIV-1 Protease," Science, 249, 527 (1990).

25

Several classes of compounds are known to be useful as inhibitors of the proteolytic enzyme renin. See, for example, U.S. No. 4,599,198; U.K. 2,184,730; G.B. 2,209,752; EP O 264 795; G.B. 2,200,115 and U.S. SIR H725. Of these, G.B. 2,200,115, GB 2,209,752, EP O 264,795, U.S. SIR H725 and U.S. 4,599,198 disclose urea-containing hydroxyethylamine renin inhibitors. G.B. 2,200,115 also discloses sulfamic acid-containing hydroxyethylamine renin inhibitors, and EP O 264 795 discloses certain sulfamic acid-containing hydroxyethylamine renin inhibitors. However, it is known

30

35

that, although renin and HIV proteases are both classified as aspartyl proteases, compounds which are effective renin inhibitors generally cannot be predicted to be effective HIV protease inhibitors.

5

BRIEF DESCRIPTION OF THE INVENTION


The present invention is directed to virus
 10 inhibiting compounds and compositions. More particularly, the present invention is directed to retroviral protease inhibiting compounds and compositions, to a method of inhibiting retroviral proteases, to processes for preparing the compounds and
 15 to intermediates useful in such processes. The subject compounds are characterized as sulfonylalkanoylamino hydroxyethylamino sulfamic acid-containing inhibitor compounds.

20

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided a retroviral protease inhibiting compound of the formula:

25



or a pharmaceutically acceptable salt, prodrug or ester thereof wherein:

30

R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl,

aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonyl, and aralkoxycarbonylalkyl radicals, aminoalkyl, and mono- and disubstituted aminoalkyl, mono- and disubstituted aminocarbonylalkyl and mono- and disubstituted aminoalkanoylalkyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl radicals, or wherein said aminoalkyl, aminocarbonylalkyl and aminoalkanoylalkyl radicals are disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;

R¹, R²⁰ and R²¹ independently represent hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃), -C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, O-alkyl serine, aspartic acid, beta-cyanoalanine and valine side chains;

R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, -NO₂, -CN, -CF₃, -OR⁹ and -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals;

R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, cycloalkyl,

cycloalkylalkyl, heterocycloalkyl, heteroaryl,
 heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl,
 aminoalkyl and mono- and disubstituted aminoalkyl
 radicals, wherein said substituents are selected from
 5 alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
 heteroaryl, heteroaralkyl, heterocycloalkyl, and
 heterocycloalkylalkyl radicals, or in the case of a
 disubstituted aminoalkyl radical, said substituents along
 with the nitrogen atom to which they are attached, form a
 10 heterocycloalkyl or a heteroaryl radical, and thioalkyl,
 alkylthioalkyl and arylthioalkyl radicals and the sulfone
 and sulfoxide derivatives thereof;

R⁴ and R⁵ independently represent hydrogen and radicals
 15 as defined by R³ or together with a nitrogen atom to
 which they are bonded form a heterocycloalkyl or a
 heteroaryl radical;

R⁶ represents hydrogen and alkyl radicals;

20


each x independently represents 1 or 2;

t represents either 0, 1, or 2; and

25 Y represents O, S and NR¹⁵ wherein R¹⁵ represents
 hydrogen and radicals as defined for R³.

A family of compounds of particular interest
 within Formula I are compounds embraced by Formula II:

30



wherein:

R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkyl, aralkoxyalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals;

10

R¹, R²⁰ and R²¹ independently represent hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃), -C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, O-methyl serine, aspartic acid, beta-cyanoalanine and valine side chains;

R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, -NO₂, -C≡N, CF₃, -OR⁹, -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals;

R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from

- alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone and sulfoxide derivatives thereof;
- 5
- 10 R⁴ and R⁵ independently represent hydrogen and radicals as defined by R³, or together with the nitrogen atom to which they are bonded represent heterocycloalkyl and heteroaryl radicals; and
- 15 t represents 0 or 1.

A more preferred family of compounds within Formula II consists of compounds wherein:

- 20 R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl,
- 25 aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals;

- R¹, R²⁰ and R²¹ independently represent hydrogen CH₂C(O)NHCH₃, C(CH₃)₂(SCH₃), C(CH₃)₂(S[O]CH₃),
- 30 C(CH₃)₂(S[O]₂CH₃), alkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, threonine, allo-threonine, isoleucine, tert-leucine, S-methyl cysteine and methionine and the sulfone and sulfoxide derivatives
- 35 thereof, alanine, and allo-isoleucine;

R² represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula
5 -OR⁹ and -SR⁹ wherein R⁹ represents alkyl radicals; and

R³ represents alkyl, haloalkyl, alkenyl, hydroxyalkyl, thioalkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl,
10 aryl, aralkyl, heteroaryl and heteroaralkyl radicals;

R⁴ and R⁵ independently represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl
15 radicals, or R⁴ and R⁵ together with the nitrogen atom to which they are bonded from a heterocycloalkyl or heteroaryl radical; and

t represents 0 or 1.

20

Of highest interest are compounds within Formula II wherein

R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonyl and aralkoxycarbonylalkyl radicals;
25

30

R¹, R²⁰ and R²¹ independently represent hydrogen CH₂C(O)NHCH₃, C(CH₃)₂(SCH₃), C(CH₃)₂(S[O]CH₃), C(CH₃)₂(S[O]₂CH₃), methyl, propargyl, t-butyl, isopropyl and sec-butyl radicals, and amino acid side chains
35 selected from the group consisting of asparagine, valine,


S-methyl cysteine, methionine, allo-iso-leucine, iso-leucine, and beta-cyano alanine side chains;

R² represents CH₃SCH₂CH₂-, iso-butyl, n-butyl, benzyl,
5 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;

R³ represents propyl, isoamyl, n-butyl, isobutyl, cyclohexyl, cyclohexylmethyl, benzyl and pyridylmethyl
10 radicals;

R⁴ and propyl independently represent hydrogen and methyl, cyclohexyl, ethyl, i-propyl, n-butyl, t-butyl, 1,1-dimethylpropyl, and phenyl radicals, or together with
15 the nitrogen atom to which they are bonded form a pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl or N'-alkylpiperazinyl radical; and t is 0.

Another family of compounds of particular
20 interest within Formula I are compounds embraced by Formula III:



25 wherein:

R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl,
30 aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals;

- R¹, R²⁰ and R²¹ independently represent hydrogen,
-CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂, -CH₂C(O)NHCH₃,
-C(CH₃)₂(SH), -C(CH₃)₂(SCH₃), -C(CH₃)₂(S[O]CH₃),
5 -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl
and cycloalkyl radicals, and amino acid side chains
selected from asparagine, S-methyl cysteine and
methionine and the sulfoxide (SO) and sulfone (SO₂)
derivatives thereof, isoleucine, allo-isoleucine,
10 alanine, leucine, tert-leucine, phenylalanine, ornithine,
histidine, norleucine, glutamine, threonine, glycine,
allo-threonine, serine, aspartic acid, beta-cyano alanine
and valine side chains;
- 15 R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl
and aralkyl radicals, which radicals are optionally
substituted with a group selected from alkyl and halogen
radicals, -NO₂, -C≡N, CF₃, -OR⁹, -SR⁹, wherein R⁹
represents hydrogen and alkyl radicals;
- 20 R³ represents alkyl, haloalkyl, alkenyl, alkynyl,
hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heteroaryl,
heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl,
25 aminoalkyl and mono- and disubstituted aminoalkyl
radicals, wherein said substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroaralkyl, heterocycloalkyl, and
heterocycloalkylalkyl radicals, or in the case of a
30 disubstituted aminoalkyl radical, said substituents along
with the nitrogen atom to which they are attached, form a
heterocycloalkyl or a heteroaryl radical, and thioalkyl,
alkylthioalkyl and arylthioalkyl radicals and the sulfone
and sulfoxide derivatives thereof; and
- 35

R⁴ and R⁵ independently represent hydrogen and radicals as defined for R³ or together with a nitrogen atom to which they are bonded form a heterocycloalkyl or a heteroaryl radical.

5

A more preferred family of compounds within Formula III consists of compounds wherein

R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals;

15

R¹, R²⁰ and R²¹ independently represent hydrogen, alkyl and alkenyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, threonine, allo-threonine, isoleucine, tert-leucine, S-methyl cysteine and methionine and the sulfone and sulfoxide derivatives thereof, alanine, and allo-isoleucine;

20

R² represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula -OR⁹ and -SR⁹ wherein R⁹ represents hydrogen and alkyl radicals;

25

R³ represents alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkoxyalkyl, thioalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl radicals; and

30

35

R⁴ and R⁵ independently represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals, or R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a heterocycloalkyl or heteroaryl radical.

Of highest interest are compounds within Formula III wherein

10

R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals;

R¹, R²⁰ and R²¹ independently represent hydrogen, methyl, ethyl, propargyl, t-butyl, isopropyl and sec-butyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, S-methyl cysteine, methionine, allo-iso-leucine, iso-leucine, threonine, serine, aspartic acid, beta-cyano alanine, and allo-threonine side chains;


30

R² represents CH₃SCH₂CH₂-, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;

R³ represents propyl, isobutyl, isoamyl, n-butyl, cyclohexyl, cyclohexylmethyl, benzyl and pyridylmethyl radicals; and

R^4 and R^5 independently represent hydrogen and methyl, ethyl, propyl, i-propyl, n-butyl, t-butyl, 1,1-dimethylpropyl, cyclohexyl and phenyl radicals, or R^4 and R^5 together with the nitrogen atom to which they are
 5 bonded form a pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl or N'-alkylpiperazinyl radical.

Another family of compounds of particular interest within Formula I are compounds embraced by
 10 Formula IV:



wherein:

15 R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl,
 20 aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals;

R^1 , R^{20} and R^{21} independently represent hydrogen, $-\text{CH}_2\text{SO}_2\text{NH}_2$, $-\text{CH}_2\text{CO}_2\text{CH}_3$, $-\text{CO}_2\text{CH}_3$, $-\text{CONH}_2$, $-\text{CH}_2\text{C}(\text{O})\text{NHCH}_3$,
 25 $-\text{C}(\text{CH}_3)_2(\text{SH})$, $-\text{C}(\text{CH}_3)_2(\text{SCH}_3)$, $-\text{C}(\text{CH}_3)_2(\text{S}(\text{O})\text{CH}_3)$, $-\text{C}(\text{CH}_3)_2(\text{S}(\text{O})_2\text{CH}_3)$, alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO₂)
 30 derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine,

allo-threonine, serine, aspartic acid, beta-cyano alanine and valine side chains;

- R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, -NO₂, -C≡N, CF₃, -OR⁹ and -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals;
- 10 R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from
- 15 alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along
- 20 with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone and sulfoxide derivatives thereof; and
- 25 R⁴ and R⁵ independently represent hydrogen and radicals as defined by R³, or together with the nitrogen atom to which they are bonded represent heterocycloalkyl and heteroaryl radicals.

- 30 A more preferred family of compounds within Formula IV consists of compounds wherein

- R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl,
- 35

aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals;

5

R¹, R²⁰ and R²¹ independently represent hydrogen and alkyl radicals having from 1 to about 4 carbon atoms, alkenyl, alkynyl, aralkyl radicals, and radicals selected from -CH₂SO₂NH₂, -CO₂CH₃, -CONHCH₃, -CON(CH₃)₂,
10 -CH₂C(O)NHCH₃, -CH₂C(O)N(CH₃)₂, -CONH₂, -C(CH₃)₂(SCH₃), -C(CH₃)₂(S[O]CH₃) and -C(CH₃)₂(S[O]₂CH₃).

R² represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with
15 halogen radicals and radicals represented by the formula -OR⁹ and -SR⁹ wherein R⁹ represents hydrogen and alkyl radicals; and

R³ represents alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl radicals; and

R⁴ and R⁵ independently represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals, or R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a heterocycloalkyl or heteroaryl radical.

30

Of highest interest are compounds of Formula IV wherein:

R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl,

aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals;

5

R¹, R²⁰ and R²¹ independently represent hydrogen, methyl, ethyl, benzyl, phenylpropyl, -C(O)NH₂ and propargyl radicals;

10 R² represents CH₃SCH₂CH₂-, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;

R³ represents propyl, isobutyl, isoamyl, n-butyl,
15 cyclohexylmethyl, benzyl and pyridylmethyl radicals; and

R⁴ and R⁵ independently represent hydrogen and methyl, ethyl, i-propyl, n-butyl, t-butyl, 1,1-dimethylpropyl and phenyl radicals, or together with the nitrogen atom to
20 which they are bonded form a pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl or N'-alkylpiperazinyl radical.

As utilized herein, the term "alkyl", alone or in combination, means a straight-chain or branched-chain
25 alkyl radical containing from 1 to about 10, preferably from 1 to 8, carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the like. The term "alkenyl", alone or in
30 combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to about 18 carbon atoms preferably from 2 to 8 carbon atoms. Examples of suitable alkenyl radicals include ethenyl, propenyl, 1,4-butadienyl,
35 12-octadecene and the like. The term "alkynyl", alone or in combination, means a straight-chain hydrocarbon

radical having one or more triple bonds and containing from 2 to about 10 carbon atoms, preferably from 2 to 8 carbon atoms. Examples of alkynyl radicals include ethynyl, propynyl, (propargyl), butynyl and the like.

- 5 The term "alkoxy", alone or in combination, means an alkyl ether radical wherein the term alkyl is as defined above. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like. The
- 10 term "cycloalkyl", alone or in combination means a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl radical wherein each cyclic moiety contains from about 3 to about 8 carbon atoms and is cyclic. The term "cycloalkylalkyl" means an alkyl
- 15 radical as defined above which is substituted by a cycloalkyl radical containing from about 3 to about 8, preferably from 3 to 6 carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. The term "aryl",
- 20 alone or in combination, means a phenyl or naphthyl radical which optionally carries one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, haloalkyl and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl,
- 25 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the like. The term "aralkyl", alone or in combination, means an alkyl radical as defined above in which one hydrogen atom is replaced by an aryl radical as defined above, such as
- 30 benzyl, 2-phenylethyl and the like. The term "aralkoxy carbonyl", alone or in combination, means a radical of the formula $-C(O)-O-$ aralkyl in which the term "aralkyl" has the significance given above. An example of an aralkoxycarbonyl radical is benzyloxycarbonyl. The term
- 35 "aryloxy" means a radical of the formula aryl-O- in which the term aryl has the significance given above. The term

"alkanoyl", alone or in combination, means an acyl radical derived from an alkanecarboxylic acid wherein alkane means a radical as defined above for alkyl. Examples of alkanoyl radicals include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like. The term "cycloalkylcarbonyl" means an acyl group derived from a monocyclic or bridged cycloalkanecarboxylic acid such as cyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a benz-fused monocyclic cycloalkanecarboxylic acid which is optionally substituted by, for example, alkanoylamino, such as 1,2,3,4-tetrahydro-2-naphthoyl, 2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl. The term "aralkanoyl" means an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl, and the like. The term "aroyl" means an acyl radical derived from an aromatic carboxylic acid. Examples of such radicals include aromatic carboxylic acids, an optionally substituted benzoic or naphthoic acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2-naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like. The heterocyclyl or heterocycloalkyl portion of a heterocyclylcarbonyl, heterocyclloxycarbonyl, heterocyclylalkoxycarbonyl, or heterocyclalkyl group or the like is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle which contains one or more hetero atoms selected from nitrogen, oxygen and sulphur, which is optionally substituted on one or more carbon atoms by halogen, alkyl, alkoxy, oxo, and the like, and/or on a secondary nitrogen atom (i.e.,

- NH-) by alkyl, aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiary nitrogen atom (i.e. = N-) by oxido and which is attached via a carbon atom. The heteroaryl portion of a heteroaroyl,
- 5 heteroaryloxycarbonyl, or a heteroaralkoxy carbonyl group or the like is an aromatic monocyclic, bicyclic, or tricyclic heterocycle which contains the hetero atoms and is optionally substituted as defined above with respect to the definition of heterocyclyl. Such heterocyclyl and
- 10 heteroaryl radicals have from four to about 12 ring members, preferably from 4 to 10 ring members. Examples of such heterocyclyl and heteroaryl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol
- 15 4-yl, 1-benzyloxycarbonylimidazol-4-yl, etc.), pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, furyl, thienyl, triazolyl, oxazolyl, thiazolyl, indolyl (e.g., 2-indolyl, etc.), quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl, 1-oxido-2-quinolinyl, etc.), isoquinolinyl (e.g.,
- 20 1-isoquinolinyl, 3-isoquinolinyl, etc.), tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydro-2-quinolyl, etc.), 1,2,3,4-tetrahydroisoquinolinyl (e.g., 1,2,3,4-tetrahydro-1-oxo-isoquinolinyl, etc.), quinoxalinyl, β -carbolinyl, 2-benzofurancarbonyl,
- 25 1-,2-,4- or 5-benzimidazolyl, and the like. The term "cycloalkylalkoxycarbonyl" means an acyl group derived from a cycloalkylalkoxycarboxylic acid of the formula cycloalkylalkyl-O-COOH wherein cycloalkylalkyl has the significance given above. The term "aryloxyalkanoyl"
- 30 means an acyl radical of the formula aryl-O-alkanoyl wherein aryl and alkanoyl have the significance given above. The term "heterocyclylloxycarbonyl" means an acyl group derived from heterocyclyl-O-COOH wherein heterocyclyl is as defined above. The term
- 35 "heterocyclylalkanoyl" is an acyl radical derived from a heterocyclyl-substituted alkane carboxylic acid wherein

heterocyclyl has the significance given above. The term "heterocyclylalkoxycarbonyl" means an acyl radical derived from a heterocyclyl-substituted alkane-O-COOH wherein heterocyclyl has the significance given above.

- 5 The term "heteroaryloxycarbonyl" means an acyl radical derived from a carboxylic acid represented by heteroaryl-O-COOH wherein heteroaryl has the significance given above. The term "aminocarbonyl" alone or in combination, means an amino-substituted carbonyl (carbamoyl) group
- 10 derived from an amino-substituted carboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like. The term
- 15 "aminoalkanoyl" means an acyl group derived from an amino-substituted alkanecarboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl
- 20 radicals and the like. The term "halogen" means fluorine, chlorine, bromine or iodine. The term "haloalkyl" means an alkyl radical having the significance as defined above wherein one or more hydrogens are replaced with a halogen. Examples of such
- 25 haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like. The term "leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol
- 30 nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein
- 35 where appropriate.


Procedures for preparing the compounds of Formula I are set forth below. It should be noted that the general procedure is shown as it relates to preparation of compounds having the specified stereochemistry, for example, wherein the absolute stereochemistry about the hydroxyl group is designated as (R), which is the preferred stereochemistry for the compounds of the present invention. However, such procedures are generally applicable to those compounds of opposite configuration, e.g., where the stereochemistry about the hydroxyl group is (S). In addition, the compounds having the (R) stereochemistry can be utilized to produce those having the (S) stereochemistry. For example, a compound having the (R) stereochemistry can be inverted to the (S) stereochemistry using well-known methods.

Preparation of Compounds of Formula I


20

The compounds of the present invention represented by Formula I above can be prepared utilizing the following general procedure. This procedure is schematically shown in the following Schemes I and II:

25


SCHEME I

a) amine b) sulfamoyl chloride R⁴R⁵NSO₂Cl (or anhydride)
+ acid scavenger d) coupling.

SCHEME II

a) amine b) sulfamoyl chloride $R^4R^5NSO_2Cl$ (or anhydride)
+ acid scavenger d) coupling.

An N-protected chloroketone derivative of an amino acid having the formula:



5


wherein P represents an amino protecting group, and R² is as defined above, is reduced to the corresponding alcohol utilizing an appropriate reducing agent. Suitable amino protecting groups are well known in the art and include carbobenzoxy, t-butoxycarbonyl, and the like. A preferred amino protecting group is carbobenzoxy. A preferred N-protected chloroketone is N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone. A preferred reducing agent is sodium borohydride. The reduction reaction is conducted at a temperature of from -10°C to about 25°C, preferably at about 0°C, in a suitable solvent system such as, for example, tetrahydrofuran, and the like. The N-protected chloroketones are commercially available, e.g., such as from Bachem, Inc., Torrance, California. Alternatively, the chloroketones can be prepared by the procedure set forth in S. J. Fittkau, J. Prakt. Chem., 315, 1037 (1973), and subsequently N-protected utilizing procedures which are well known in the art.

25

The halo alcohol can be utilized directly, as described below, or, preferably, is then reacted, preferably at room temperature, with a suitable base in a suitable solvent system to produce an N-protected amino epoxide of the formula:


30

25




wherein P and R² are as defined above. Suitable solvent systems for preparing the amino epoxide include ethanol, methanol, isopropanol, tetrahydrofuran, dioxane, and the like including mixtures thereof. Suitable bases for producing the epoxide from the reduced chloroketone include potassium hydroxide, sodium hydroxide, potassium t-butoxide, DBU and the like. A preferred base is potassium hydroxide.

Alternatively, a protected amino epoxide can be prepared starting with an L-amino acid which is reacted with a suitable amino-protecting group in a suitable solvent to produce an amino-protected L-amino acid ester of the formula:



wherein P¹ and P² independently represent hydrogen, benzyl and amino-protecting groups (as defined above), provided that P¹ and P² are not both hydrogen; P³ represents carboxyl-protecting group, e.g., methyl, ethyl, benzyl, tertiary-butyl and the like; and R² is as defined above.


The amino-protected L-amino acid ester is then reduced, to the corresponding alcohol. For example, the amino-protected L-amino acid ester can be reduced with diisobutylaluminum hydride at -78°C in a suitable solvent such as toluene. The resulting alcohol is then converted, for example, by way of a Swern oxidation, to the corresponding aldehyde of the formula:



10


wherein P^1 , P^2 and R^2 are as defined above. Thus, a dichloromethane solution of the alcohol is added to a cooled (-75 to -68°C) solution of oxalyl chloride in dichloromethane and DMSO in dichloromethane and stirred for 35 minutes.

The aldehyde resulting from the Swern oxidation is then reacted with a halomethyl lithium reagent, which reagent is generated in situ by reacting an alkyl lithium or aryllithium compound with a dihalomethane represented by the formula $X^1\text{CH}_2\text{X}^2$ wherein X^1 and X^2 independently represent I, Br or Cl. For example, a solution of the aldehyde and chloriodomethane in THF is cooled to -78°C and a solution of n-butyllithium in hexane is added. The resulting product is a mixture of diastereomers of the corresponding amino-protected epoxides of the formulas:




The diastereomers can be separated e.g., by chromatography, or, alternatively, once reacted in subsequent steps the diastereomeric products can be separated. For compounds having the (S) stereochemistry, a D-amino acid can be utilized in place of the L-amino acid.

The amino epoxide is then reacted, in a suitable solvent system, with an equal amount, or preferably an excess of, a desired amine of the formula:




wherein R^3 is hydrogen or is as defined above. The reaction can be conducted over a wide range of temperatures, e.g., from about 10°C to about 100°C, but is preferably, but not necessarily, conducted at a temperature at which the solvent begins to reflux. Suitable solvent systems include protic, non-protic and dipolar aprotic organic solvents such as, for example, those wherein the solvent is an alcohol, such as methanol, ethanol, isopropanol, and the like, ethers such as tetrahydrofuran, dioxane and the like, and toluene, N,N-dimethylformamide, dimethyl sulfoxide, and mixtures thereof. A preferred solvent is isopropanol. Exemplary amines corresponding to the formula R^3NH_2 include benzyl amine, isobutylamine, n-butyl amine, isopentyl amine, isoamylamine, cyclohexanemethyl amine, naphthylene methyl amine and the like. The resulting product is a 3-(N-protected amino)-3-(R^2)-1-(NHR^3)-propan-2-ol derivative (hereinafter referred to as an amino alcohol) can be represented by the formulas:



wherein P, P¹, P², R² and R³ are as described above.
 Alternatively, a haloalcohol can be utilized in place of
 5 the amino epoxide.

The amino alcohol defined above is then reacted
 in a suitable solvent with a sulfamoyl halide, e.g.
 sulfamoyl chloride (R⁴R⁵NSO₂Cl or R⁴HNSO₂Cl) or sulfamoyl
 10 anhydride in the presence of an acid scavenger. Suitable
 solvents in which the reaction can be conducted include
 methylene chloride, tetrahydrofuran and the like.
 Suitable acid scavengers include triethylamine, pyridine
 and the like. The resulting sulfamic acid derivative can
 15 be represented, depending on the epoxide utilized, by the
 formulas;



20 wherein P, P¹, P², R², R³, R⁴ and R⁵ are as defined
 above. These intermediates are useful for preparing
 inhibitor compounds of the present invention and are also
 active inhibitors of retroviral proteases.

25 The sulfamoyl halides of the formula R⁴NHSO₂X
 can be prepared by the reaction of a suitable isocyanate
 of the formula R⁴NCO with fuming sulfuric acid to produce
 the corresponding sulfamate which is then converted to


the halide by well known procedures, such as by treating the sulfamate with PCl_5 . Alternatively, the isocyanate can be treated with chlorosulfonic acid to produce the corresponding sulfamoyl chloride directly.

5

The sulfamoyl halides of the formula $\text{R}^4\text{R}^5\text{NSO}_2\text{Cl}$ can be prepared by reacting an amine of the formula $\text{R}^4\text{R}^5\text{NH}$, preferably as a salt such as the hydrochloride, with sulfonyl chloride in a suitable solvent such as acetonitrile. The reaction mixture is gradually warmed to reflux temperature and maintained at the reflux temperature until the reaction is complete. Alternatively, sulfamoyl halides of the formula $\text{R}^4\text{R}^5\text{NSO}_2\text{Cl}$ can be prepared by reacting an amine of the formula $\text{R}^4\text{R}^5\text{NH}$ with sulfonyl chloride in boiling MeCN as disclosed in Matier et al., J. Med. Chem., 15, No. 5, p.538 (1972).

Following preparation of the sulfamic acid derivative, the amino protecting group P or the P^1 and P^2 amino protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of the protecting group, e.g., removal of a carbobenzoxy group, by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. Where the protecting group is a t-butoxycarbonyl group, it can be removed utilizing an inorganic or organic acid, e.g., HCl or trifluoroacetic acid, in a suitable solvent system, e.g., dioxane or methylene chloride. The resulting product is the amine salt derivative. Where the protecting group is a benzyl radical, it can be removed by hydrogenolysis.


Following neutralization of the salt, the amine is then reacted with a sulfone of the formula



5

wherein R, R¹, R²⁰, R²¹ and t are as defined above. The sulfone is prepared according to the following procedure to produce the antiviral compounds of the present invention having the formula:


10



wherein R, R¹, R², R³, R⁴, R⁵, R²⁰, R²¹ and t are as defined above. The sulfone is prepared according to the following procedure.

15


A mercaptan of the formula RSH is reacted with a substituted methacrylate of the formula:



20


by way of a Michael Addition. The Michael Addition is conducted in a suitable solvent and in the presence of a suitable base, to produce the corresponding thiol derivative represented by the formula:

25



wherein R and R¹ represent radicals defined above; R²⁰ and
 5 R²¹ represent hydrogen and radicals as defined for R¹; and
 R²² represents a carboxyl protecting group such as methyl,
 ethyl, benzyl, t-butyl or the like. Suitable solvents in
 which the Michael Addition can be conducted include protic,
 non-protic and dipolar aprotic organic solvents, e.g.,
 10 alcohols such as, for example, methanol, ethanol, butanol
 and the like, as well as ethers, e.g., THF, and
 acetonitrile, DMF, DMSO, and the like, including mixtures
 thereof. Suitable bases include Group I metal alkoxides
 such as, for example sodium methoxide, sodium ethoxide,
 15 sodium butoxide and the like as well as Group I metal
 hydrides, such as sodium hydride, including mixtures
 thereof.


The thiol derivative is converted into the
 20 corresponding sulfone or sulfoxide of the formula:



by oxidizing the thiol derivative with a suitable oxidation
 25 agent in a suitable solvent. Suitable oxidation agents
 include, for example, hydrogen peroxide, sodium meta-
 perborate, oxone (potassium peroxy monosulfate), meta-
 chloroperoxybenzoic acid, periodic acid and the like,
 including mixtures thereof. Suitable solvents include

acetic acid (for sodium ~~meta~~-perborate) and, for other peracids, ethers such as THF and dioxane, and acetonitrile, DMF and the like, including mixtures thereof.

- 5 The sulfone is then converted to the corresponding free acid of the formula:




- One method involves utilizing a suitable base, e.g., lithium hydroxide, sodium hydroxide, and the like, including mixtures thereof, in a suitable solvent, such as, for example, THF, water, acetonitrile, DMF, DMSO, methylene chloride and the like, including mixtures thereof. Other methods which can be used for deprotection depend on the nature of R²². For example, when R²² is a tertiary-butyl group, one can use a strong acid such as hydrochloric acid or trifluoroacetic acid. When R²² is a benzyl group, it can be removed via hydrogenolysis.


- 20 The free acid is then coupled, utilizing procedures well known in the art, to the sulfamate derivative, or analog thereof, of an amino alcohol which is described above. The resulting product is a compound represented by Formula I.

25


Alternatively, one can couple the sulfamate isostere to the commercially available acid,



remove the thioacetyl group with a suitable base, such as hydroxide, or an amine, such as ammonia, and then react the resulting thiol with an alkylating agent, such as an alkyl halide, tosylate or mesylate to afford compounds at the
 5 following structure:




The sulfur can then be oxidized to the
 10 corresponding sulfone or sulfoxide using suitable oxidizing agents, as described above, to afford the desired compounds of the following structure:



15


Alternatively, to prepare compounds of Formula I, a substituted methacrylate of the formula:



20

wherein L represents a leaving group as previously defined, R³⁵ and R³⁶ represent hydrogen and radicals as defined for R¹; and R³⁷ represents alkyl, aralkyl, cycloalkyl and cycloalkylalkyl radicals, is reacted with a suitable
 25 sulfonating agent, such as, for example, a sulfinic acid represented by the formula RSO₂M, wherein R represents


radicals as defined above and M represents a metal adapted to form a salt of the acid, e.g., sodium, to produce the corresponding sulfone represented by the formula:



5

wherein R, R³⁵, R³⁶ and R³⁷ are as defined above. The sulfone is then hydrolyzed in the presence of a suitable base, such as lithium hydroxide, sodium hydroxide and the like, to the compound represented by the formula:


10



wherein R, R³⁵ and R³⁶ represent radicals as defined above. The resulting compound is then asymmetrically hydrogenated utilizing an asymmetric hydrogenation catalyst such as, for example, a ruthenium-BINAP complex, to produce the reduced product, substantially enriched in the more active isomer, represented by the formula:

15

20




wherein R, R³⁵ and R³⁶ represent radicals as defined above. Where the more active isomer has the R-stereochemistry, a Ru(R-BINAP) asymmetric hydrogenation catalyst can be utilized. Conversely, where the more active isomer has the

25

S-stereochemistry, a Ru(S-BINAP) catalyst can be utilized. Where both isomers are active, or where it is desired to have a mixture of the two diastereomers, a hydrogenation catalyst such as platinum, or palladium, on carbon can be
5 utilized to reduce the above compound. The reduced compound is then coupled to the sulfamate isostere, as described above, to produce compounds of Formula II.

Alternatively, an acid or a derivative of an acid
10 properly substituted with a leaving group (discussed above) can be treated with a mercaptan and a base (see above) to provide an organic sulfide. Acid derivatives are defined above. The resulting sulfide can be oxidized to the
15 corresponding sulfoxide or sulfone by methods previously discussed.


A preferred method to prepare 2(S)-methyl-3-(methylsulfonyl)propionic acid is as follows. Beginning
20 with the commercially available compounds of the following structure;



Where P³ is a protecting group for sulfur, preferably a
25 benzoyl or acetyl, and P⁴ is either hydrogen or a carboxylic acid protecting group such as methyl, ethyl, tertiary-butyl, benzyl and the like. Preferably, P⁴ is tertiary-butyl. The sulfur protecting group P³ can be selectively removed using methods known to those skilled in the art. For example,
30 where P³ is either benzoyl or acetyl, it can be removed by treatment with an inorganic base or an amine, preferably ammonia, in an appropriate solvent such as methanol, ethanol, isopropanol, toluene or tetrahydrofuran. The

36

preferred solvent is methanol. This provides a compound of the following structure;




5

which can be alkylated on the sulfur with a compound of the structure

RX

10

Where R is as defined above, and X is an appropriate leaving group, such as a halide (chloride, bromide, iodide), mesylate, tosylate or triflate. The reaction is performed in the presence of a suitable base, such as triethylamine, diisopropylethylamine, 1,8-diazabicyclo[5.4.0] undec-7-ene (DBU) and the like, in a suitable solvent such as toluene, tetrahydrofuran, or methylene chloride. The preferred base is DBU and the preferred solvent is toluene. Where R is a methyl group, RX can be methyl chloride, methyl bromide, methyl iodide, or dimethyl sulfate. Preferably RX is methyl iodide. The product of the reaction is a compound of the structure;




25

The sulfur can then be oxidized to either the sulfoxide or sulfone using methods known to those skilled in the art. Suitable oxidizing agents are meta-chloroperbenzoic acid, hydrogen peroxide, sodium perborate and the like.


Appropriate solvents are methylene chloride, toluene, acetic

acid, propionic acid and the like. The preferred method is using hydrogen peroxide or sodium perborate in acetic acid. The sulfone product has the structure;



5


The carboxylic acid protecting group P^4 can then be removed using methods well known to those in the art. For example, when P^4 is a tertiary-butyl group, it can be removed by
 10 treatment with an acid, such as hydrochloric acid or trifluoroacetic acid. The preferred method is using 4N hydrochloric acid in dioxane. This provides the desired final compound of the structure;




15

Alternatively, the protected amino alcohol from the epoxide opening can be further protected at the newly introduced amino group with a protecting group P' which
 20 is not removed when the first protecting P is removed. One skilled in the art can choose appropriate combinations of P and P' . One suitable choice is when P is Cbz and P' is Boc. The resulting compound represented by the formula:

25



can be carried through the remainder of the synthesis to provide a compound of the formula:



5

and the new protecting group P' is selectively removed, and following deprotection, the resulting amine reacted to form the sulfamic acid derivative as described above. This selective deprotection and conversion to the
10 sulfamic acid can be accomplished at either the end of the synthesis or at any appropriate intermediate step if desired.

It is contemplated that for preparing compounds
15 of the Formulas having R⁶, the compounds can be prepared following the procedure set forth above and, prior to coupling the sulfamate derivative or analog thereof, e.g. coupling to the amino acid PNH(CH₂)_tCH(R¹)COOH, carried through a procedure referred to in the art as reductive
20 amination. Thus, a sodium cyanoborohydride and an appropriate aldehyde or ketone can be reacted with the sulfamate derivative compound or appropriate analog at room temperature in order to reductively aminate any of the compounds of Formulas I-IV. It is also contemplated
25 that where R³ of the amino alcohol intermediate is hydrogen, the inhibitor compounds of the present invention wherein R³ is alkyl, or other substituents wherein the α-C contains at least one hydrogen, can be prepared through reductive amination of the final product
30 of the reaction between the amino alcohol and the amine or at any other stage of the synthesis for preparing the inhibitor compounds.

Contemplated equivalents of the general formulas set forth above for the antiviral compounds and derivatives as well as the intermediates are compounds otherwise corresponding thereto and having the same general properties, such as tautomers thereof as well as compounds, wherein one or more of the various R groups are simple variations of the substituents as defined therein, e.g., wherein R is a higher alkyl group than that indicated. In addition, where a substituent is designated as, or can be, a hydrogen, the exact chemical nature of a substituent which is other than hydrogen at that position, e.g., a hydrocarbyl radical or a halogen, hydroxy, amino and the like functional group, is not critical so long as it does not adversely affect the overall activity and/or synthesis procedure.


The chemical reactions described above are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

All reagents were used as received without purification. All proton and carbon NMR spectra were obtained on either a Varian VXR-300 or VXR-400 nuclear magnetic resonance spectrometer.

The following Examples 1 through 9 illustrate preparation of intermediates. These intermediates are useful in preparing the inhibitor compounds of the present invention as illustrated below.

Example 1



Preparation of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-isoamylamine

Part A:

To a solution of 75.0g (0.226 mol) of N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone in a mixture of 807 mL of methanol and 807 mL of tetrahydrofuran at -2°C, was added 13.17g (0.348 mol, 1.54 equiv.) of solid sodium borohydride over one hundred minutes. The solvents were removed under reduced

pressure at 40°C and the residue dissolved in ethyl acetate (approx. 1L). The solution was washed sequentially with 1M potassium hydrogen sulfate, saturated sodium bicarbonate and then saturated sodium chloride solutions. After drying over anhydrous magnesium sulfate and filtering, the solution was removed under reduced pressure. To the resulting oil was added hexane (approx. 1L) and the mixture warmed to 60°C with swirling. After cooling to room temperature, the solids were collected and washed with 2L of hexane. The resulting solid was recrystallized from hot ethyl acetate and hexane to afford 32.3g (43% yield) of N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol, mp 150-151°C and $M+Li^+ = 340$.

Part B:


To a solution of 6.52g (0.116 mol, 1.2 equiv.) of potassium hydroxide in 968 mL of absolute ethanol at room temperature, was added 32.3g (0.097 mol) of N-CBZ-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol. After stirring for fifteen minutes, the solvent was removed under reduced pressure and the solids dissolved in methylene chloride. After washing with water, drying over magnesium sulfate, filtering and stripping, one obtains 27.9g of a white solid. Recrystallization from hot ethyl acetate and hexane afforded 22.3g (77% yield) of N-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane, mp 102-103°C and $MH^+ 298$.

Part C:

A solution of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane (1.00g, 3.36 mmol) and isoamylamine (4.90g, 67.2 mmol, 20 equiv.) in 10 mL of isopropyl alcohol was heated to reflux for 1.5 hours. The solution was cooled to room temperature, concentrated *in vacuo* and then poured into 100 mL of stirring hexane whereupon the product crystallized from solution. The

product was isolated by filtration and air dried to give 1.18g, 95% of N=[{3(S)-phenylmethylcarbamoyl}amino-2(R)-hydroxy-4-phenylbutyl]N-[(3-methylbutyl)]amine mp 108.0-109.5°C, MH⁺ m/z = 371.

Example 2



Preparation of N,N-dibenzyl-3(S)-amino-1,2-(S)-epoxy-4-phenylbutane

Step A:

A solution of L-phenylalanine (50.0 g, 0.302 mol), sodium hydroxide (24.2 g, 0.605 mol) and potassium carbonate (83.6 g, 0.605 mol) in water (500 ml) is heated to 97°C. Benzyl bromide (108.5 ml, 0.912 mol) is then slowly added (addition time ~25 min). The mixture is then stirred at 97°C for 30 minutes. The solution is cooled to room temperature and extracted with toluene (2 x 250 ml). The combined organic layers are then washed with water, brine, dried over magnesium sulfate, filtered and concentrated to give an oil product. The crude product is then used in the next step without purification.

Step B:

The crude benzylated product of the above step is dissolved in toluene (750 ml) and cooled to -55°C. A 1.5 M solution of DIBAL-H in toluene (443.9 ml, 0.666

mol) is then added at a rate to maintain the temperature between -55° to -50°C (addition time - 1 hour). The mixture is stirred for 20 minutes at -55°C . The reaction is quenched at -55°C by the slow addition of methanol (37 ml). The cold solution is then poured into cold (5°C) 1.5 N HCl solution (1.8 L). The precipitated solid (approx. 138 g) is filtered off and washed with toluene. The solid material is suspended in a mixture of toluene (400 ml) and water (100 ml). The mixture is cooled to 5°C , treated with 2.5 N NaOH (186 ml) and then stirred at room temperature until the solid is dissolved. The toluene layer is separated from the aqueous phase and washed with water and brine, dried over magnesium sulfate, filtered and concentrated to a volume of 75 ml (89 g). Ethyl acetate (25 ml) and hexane (25 ml) are then added to the residue upon which the alcohol product begins to crystallize. After 30 min., an additional 50 ml hexane is added to promote further crystallization. The solid is filtered off and washed with 50 ml hexane to give approximately 35 g of material. A second crop of material can be isolated by refiltering the mother liquor. The solids are combined and recrystallized from ethyl acetate (20 ml) and hexane (30 ml) to give, in 2 crops, approximately 40 g (40% from L-phenylalanine) of analytically pure alcohol product. The mother liquors are combined and concentrated (34 g). The residue is treated with ethyl acetate and hexane which provides an additional 7 g (~7% yield) of slightly impure solid product. Further optimization in the recovery from the mother liquor is probable.

Step C:

A solution of oxalyl chloride (8.4 ml, 0.096 mol) in dichloromethane (240 ml) is cooled to -74°C . A solution of DMSO (12.0 ml, 0.155 mol) in dichloromethane (50 ml) is then slowly added at a rate to maintain the temperature at -74°C (addition time ~1.25 hr). The

mixture is stirred for 5 min. followed by addition of a solution of the alcohol (0.074 mol) in 100 ml of dichloromethane (addition time -20 min., temp. -75°C to -68°C). The solution is stirred at -78°C for 35 minutes. Triethylamine (41.2 ml, 0.295 mol) is then added over 10 min. (temp. -78° to -68°C) upon which the ammonium salt precipitated. The cold mixture is stirred for 30 min. and then water (225 ml) is added. The dichloromethane layer is separated from the aqueous phase and washed with water, brine, dried over magnesium sulfate, filtered and concentrated. The residue is diluted with ethyl acetate and hexane and then filtered to further remove the ammonium salt. The filtrate is concentrated to give the desired aldehyde product. The aldehyde was carried on to the next step without purification.


Temperatures higher than -70°C have been reported in the literature for the Swern oxidation. Other Swern modifications and alternatives to the Swern oxidations are also possible.

A solution of the crude aldehyde 0.074 mol and chloriodomethane (7.0 ml, 0.096 mol) in tetrahydrofuran (285 ml) is cooled to -78°C. A 1.6 M solution of n-butyllithium in hexane (25 ml, 0.040 mol) is then added at a rate to maintain the temperature at -75°C (addition time - 15 min.). After the first addition, additional chloriodomethane (1.6 ml, 0.022 mol) is added again, followed by n-butyllithium (23 ml, 0.037 mol), keeping the temperature at -75°C. The mixture is stirred for 15 min. Each of the reagents, chloriodomethane (0.70 ml; 0.010 mol) and n-butyllithium (5 ml, 0.008 mol) are added 4 more times over 45 min. at -75°C. The cooling bath is then removed and the solution warmed to 22°C over 1.5 hr. The mixture is poured into 300 ml of saturated aq. ammonium chloride solution. The tetrahydrofuran layer is separated. The aqueous phase is extracted with ethyl

acetate (1 x 300 ml). The combined organic layers are washed with brine, dried over magnesium sulfate, filtered and concentrated to give a brown oil (27.4 g). The product could be used in the next step without purification. The desired diastereomer can be purified by recrystallization at a subsequent step.


Alternately, the product could be purified by chromatography.

Example 3



Preparation of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenyl]N-isobutylamine

A solution of N-benzyloxycarbonyl-3(S)-amino-1,2-(S)-epoxy-4-phenyl butane (50.0 g, 0.168 mol) and isobutylamine (246 g, 3.24 mol, 20 equivalents) in 650 mL of isopropyl alcohol was heated to reflux for 1.25 hours. The solution was cooled to room temperature, concentrated in vacuo and then poured into 1 L of stirring hexane whereupon the product crystallized from solution. The product was isolated by filtration and air dried to give 57.56 g, 92% of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenyl]N-isobutylamine, mp 108.0-109.5 °C, MH⁺ m/z=371.

Example 4

Preparation of phenylmethyl[2R-hydroxy-3-
[[(dimethylamino)sulfonyl] (2-methylpropyl) amino]-1S-
(phenylmethyl)propyl]carbamate


Part A

The procedure described in Example 3 was used to prepare N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-isobutylamine.

Part B

The product from Part A (740 mg, 2.0 mmol) and diisopropylethylamine (382 μ L, 2.2 mmol) were dissolved in dichloromethane (1.5 mL) at room temperature. To this was added dimethylsulfonyl chloride (354 μ L, 3.3 mmol). The reaction was stirred for 24 hours. The reaction mixture was chromatographed on silica gel (50 gm) using 1% ethanol in chloroform. The product fractions were pooled and concentrated to an oil. Anal. Calcd for $C_{24}H_{35}N_3O_5S$:

C, 60.35; H, 7.39; N, 8.80. Found: C, 60.18; H, 7.40; N, 8.55.

Example 5


Preparation of phenylmethyl[2R-hydroxy-3-
 [(dimethylamino)sulfonyl](3-methylbutyl)amino]-1S-
 (phenylmethyl)propyl]carbamate

Part A

The procedure described in Example 1 was used to prepare N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-[(3-methylbutyl)amine].

Part B

The product from Part A (192 mg, 0.5 mmol) and diisopropylethylamine (96 μ L, 0.55 mmol) were dissolved in dichloromethane (10 mL) at room temperature. To this was added dimethylsulfamoyl chloride (59 μ L, 0.55 mmol). The reaction was stirred for 120 hours, then concentrated on a rotary evaporator. The residue was chromatographed on silica gel (50 gm) using 2% methanol in dichloromethane. The product fractions were pooled and concentrated to an oil which solidified on standing. Anal. Calcd for $C_{25}H_{37}N_3O_5S \cdot 0.9 H_2O$: C, 59.13; H, 7.64; N, 8.27; S, 6.31. Found: C, 58.81; H, 7.38; N, 8.62; S, 6.70.

Example 6

Preparation of phenylmethyl [3-[[(butylamino)sulfonyl] (2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl] carbamate

Part A:

The procedure described in Example 3 was used to prepare N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-isobutylamine.

Part B:

To a stirred solution of 3.88 gm (2 mL) of 30% fuming sulfuric acid in nitromethane (10mL) was added dropwise n-butyliisocyanate (3.83 mL, 34 mmoles) at 0 C. After the addition was completed, the suspension was heated in an oil bath at 120 C. for 30 min. The reaction was cooled and filtered. The collected sulfamic acid crystals were air dried, wt. 4.73 gm (91%).

Part C:

A suspension of n-butyl sulfamic acid (1.92 gm, 12.53 mmoles) and phosphorus pentachloride (2.61 gm, 12.53 mmoles) in benzene (20 mL) was warmed gently to initiate gas evolution. The reaction mixture was stirred at room temperature for 0.5 h., during which time a cloudy solution resulted. The cloudy solution was heated to reflux for 0.5


h., then was concentrated. The product n-butyl sulfamoyl chloride was isolated by vacuum distillation (120 C., 300 millitorr), 730 mg (liq.) (34%).

Part D:

The amino alcohol from Part A (370 mg, 1 mmole) was dissolved in 3 mL of dichloromethane and treated with diisopropylethylamine (278 uL, 2 mmols), followed by chlorotrimethylsilane (126 uL, 1 mmole). The reaction mixture was stirred at r.t. for 1 h. n-Butyl sulfamoyl chloride from Part C (171 mg, 1 mmole) was added and the mixture was stirred at r.t. overnight. After removal of dichloromethane the oily residue was taken up in ethyl acetate and washed successively with 5% citric acid, saturated sodium bicarbonate, brine, dried over sodium sulfate and the solvent was evaporated to give 512 mg of product (oil).

The oily product (510 mg) was dissolved in dichloromethane (3 mL) and was treated with 2 mL of 4N HCl in dioxane. After 15 min. methanol (5 mL) was added and the solution was stirred for an additional 15 min. Solvent and excess reagent were evaporated. The product was isolated by silica gel chromatography to give 357 mg of phenylmethyl [3-[[(butylamino)sulfonyl] (2-methylpropyl) amino]-2R-hydroxy-1S-(phenylmethyl)propyl] carbamate. Anal. Calcd for C₂₆H₃₉N₃O₅S: C, 61.76; H, 7.77; N, 8.31. Found: C, 61.89; H, 7.66; N, 8.18.

50

Example 7

Preparation of phenylmethyl [2R-hydroxy -3-[[[4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate

Part A:


1-methylpiperazine hydrochloride (3.46 gm, 20 mmoles) was added in portions within 15 min. to a stirred solution of sulfonyl chloride (8.99 gm, 67 mmoles) in acetonitrile (40 mL). The suspension was gradually warmed to reflux and maintained at reflux temperature overnight. A brown solution was obtained. After cooling to r.t., the crystals were collected by filtration, wt. 2.3 gm. A sample of 4-methyl-1-piperazine sulfamoyl chloride.HCl was recrystallized from methanol. Anal. Calcd. for $C_5H_{12}N_2O_2Cl_2S$: C, 25.54; H, 5.14; N, 11.91; Cl, 30.16. Found: C, 25.54; H, 4.91; N, 11.91; Cl, 29.88.

Part B:

N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-isobutylamine (370 mg, 1.0 mmole), prepared according to the procedure in Example 3 was mixed with DIEA (280 μ L, 2.0 mmoles) and 4-methyl-1-piperazine sulfamoyl chloride.HCl (240 mg, 1.0 mmole) in 6 mL of dichloromethane. The reaction mixture was stirred for 5 days. After filtration, the filtrate was concentrated to an oil, which was taken up in ethyl acetate. The ethyl acetate solution

was washed with sodium bicarbonate solution, brine and dried over sodium sulfate. After evaporation, phenylmethyl [2R-hydroxy-3-[[[4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate was obtained (412 mg).

Example 8



Preparation of phenylmethyl [2R-hydroxy-3-[[[1,1-dimethyl)aminol)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate

Part A:

A 25 mL two-necked RB flask, equipped with a reflux condenser and dropping funnel and under a nitrogen atmosphere, was charged with t-butanol (207 μ L, 2.2 mmol) and 5 mL of hexane. Chlorosulfonyl isocyanate (192 μ L, 2.2 mmol) in 3 mL of hexane was added dropwise. Upon warming a homogeneous solution was obtained. The solution was heated at gentle reflux for 45 min., then was cooled to r.t. Solvent was removed under a steady stream of nitrogen. The crude t-butyl sulfamoyl chloride (a liquid) was used without further purification.

Part B:

N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-isobutylamine (370 mg, 1.0 mmole), prepared according to the procedure in Example 3 was mixed with DIEA (139 uL, 1 mmole) in 5 mL of dichloromethane. Chlorotrimethylsilane (126 uL, 1 mmole) was added. After 1 h., additional DIEA (160 uL) was added, followed by a dichloromethane solution (5mL) containing 1.1 mmole of t-butyl sulfamoyl chloride from Part A. The reaction mixture was stirred for 2 days. Solvent was removed under aspirator pressure. The oily residue was taken up in ethyl acetate and washed with 5% citric acid, saturated sodium bicarbonate, brine, dried over sodium sulfate and evaporated to an oily residue (380 mg).

The crude product was stirred in 4N HCl in dioxane (6 mL) for 15 min. After the addition of 4 mL of methanol to the reaction mixture, the solution was stirred for an additional 15 min, then concentrated to an oily residue. The product, phenylmethyl [2R-hydroxy -3-[[[(1,1-dimethylethyl)amino]sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate was obtained after silica gel chromatography (188 mg, 37%). MS (MH)⁺ = 506.

Part C:

The carbobenzyloxy protecting group of the product from Part B was removed by hydrogenolysis. Thus 1.3 grams of the product of Part B in 50 mL of methanol was hydrogenated under 50 psig of hydrogen using 0.7 g of 10% palladium-on-carbon catalyst 18 hours. The catalyst was removed by filtration and the solvent removed in vacuo to afford 0.75 g of the free amine.

Example 9

Phenylmethyl [2R-hydroxy-3-[[(piperidyl)sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl]carbamate

Part A:

The product of Example 3 (750 mg, 2.02 mmol) and triethylamine (280 uL, 2.02 mmol) were dissolved in dichloromethane (8.0 mL) at room temperature. To this was added piperidinesulfamoyl chloride (371 mg, 2.02 mmol). The reaction was stirred for 72 hours and then concentrated. The residue was chromatographed on silica gel (50 gm) using 5% methanol in dichloromethane. The product fractions were pooled and concentrated to an oil, 945 mg. TLC (silica / 5% MeOH in CH₂Cl₂) showed two spots. Rechromatographed. Anal. Calcd for C₂₇H₃₉N₃O₅S: C, 62.63; H, 7.51; N, 8.06. Found: C, 62.64; H, 7.59; N, 8.12.

Part B:

The product of Part A (430 mg) was combined with 10% Pd/C in methanol (10 mL) and hydrogenated at 5 psi for 1.4 hours at room temperature. The catalyst was removed by filtration and the solvent evaporated to afford the product as an oil, 305 mg.

Part C:

To a solution of Cbz-L-t-leucine (236 mg, 0.89 mmol) in DMF (2 mL) was added HOBt (115 mg, 0.85 mmol) and EDC (163 mg, 0.85 mmol). The reaction was stirred at room temperature for 1 hour and then a solution of the product from part B (305 mg, 0.79 mmol) in DMF (2 mL) was added. The reaction was stirred for 18 hours then concentrated. The residue was taken up in ethyl acetate and washed with 0.5% HCl solution, saturated aqueous NaHCO₃, and saturated aqueous NaCl (50 mL each). The organic solution was dried (Na₂SO₄), filtered and concentrated to a foam, 410 mg. ¹H NMR supports product.

Part D:

The product of Part C (410 mg) was combined with 10% Pd/C in methanol (10 mL) and hydrogenated at 5 psi for 2.0 hours at room temperature. The catalyst was removed by filtration and the solvent evaporated to afford the product as an foam, 320 mg.

Part E:

To a solution of the product of Part D (310 mg, 0.62 mmol) in dichloromethane (10 mL) was added diisopropylethylamine (130 uL, 0.75 mmol) and chloroacetic anhydride (117 mg, 0.68 mmol) at 0 C. The reaction was allowed to warm to room temperature and stir one hour. The solvent was removed and the residue taken up in ethyl acetate (50 mL). The organic solution was washed with 5% citric acid, saturated NaHCO₃, and saturated NaCl (50 mL each). The solution was dried (Na₂SO₄) , filtered and concentrated to give a solid, 350 mg.

Part F:

The product of Part E (350 mg, 0.61 mmol) was combined with 40% aqueous dimethylamine (380 uL, 3.05 mmol) in isopropanol (10 mL). The reaction was stirred for 18 hours then concentrated. The residue was taken up in ethyl acetate (50 mL) and washed with water, saturated NaHCO₃, and saturated NaCl (50 mL each). The solution was dried (Na₂SO₄) , filtered and concentrated to a solid. The solid was chromatographed on silica gel using 2% MeOH in dichloromethane. The product fractions were pooled and concentrated to give a white solid. Anal. Calcd for C₂₉H₅₁N₅O₅S. 0.25 H₂O: C, 59.41; H, 8.77; N, 11.94. Found: C, 59.35; H, 8.78; N, 11.63.

Example 10

Following the procedures of the previous Examples 1-9, the intermediate compounds set forth in Tables 1A, 1B and 1C were prepared.

TABLE 1A



		
R ³	R ⁴	R ⁵
isobutyl	CH ₃	CH ₃
isoamyl	CH ₃	CH ₃
isobutyl	CH ₂ CH ₂ CH ₂ CH ₃	H
isobutyl	C(CH ₃) ₃	H

TABLE 1B






Entry	R ⁴	R ⁵
1	CH ₃	CH ₃
2	H	CH ₃
3	H	(CH ₂) ₃ CH ₃
4	H	CH(CH ₃) ₂
5	H	C(CH ₃) ₃
6	H	C ₆ H ₁₁
7	H	C ₆ H ₅
8		

Table 1C



Entry	R ³	R ⁴	R ⁵
A	isobutyl	methyl	H
B	p-fluorobenzyl	methyl	methyl
C	isobutyl	isopropyl	H
D	isobutyl	NR ⁴ R ⁵ =	
E	isobutyl	phenyl	H
F	isobutyl	NR ⁴ R ⁵ =	
G	isobutyl	NR ⁴ R ⁵ =	
H	benzyl	t-butyl	H
I	cyclohexylmethyl	t-butyl	H
J	C(CH ₃) ₂ CO ₂ Me	isobutyl H	
K	cyclohexyl	t-butyl	H
L	isobutyl	(CH ₂) ₂ OCH ₂ C ₆ H ₅	H
M	isobutyl	cyclohexyl	H

The following Examples 11-14 illustrate preparation of sulfonyl alkanoyl compounds which can be coupled to the intermediate compounds of Examples 1-10 to produce inhibitor compounds of the present invention.

Example 11

5

Preparation of 2(S)-methyl-3-(methylsulfonyl)propionic Acid.

To a solution of 10g of D-(-)-S-benzoyl-b-
10 mercaptoisobutyric acid t-butyl ester in 20 mL of
methanol was bubbled in gaseous ammonia at 0°C. The
reaction was allowed to then warm to room temperature,
stirred overnight and concentrated under reduced
pressure. The resulting mixture of a solid (benzamide)
15 and liquid was filtered to provide 5.21g of a pale oil
which then solidified. This was identified as
2(S)-methyl-3-mercaptopropionic acid t-butyl ester.

To a solution of 5.21g of 2(S)-methyl-3-
20 mercaptopropionic acid t-butyl ester in 75 mL of toluene
at 0°C was added 4.50g of 1,8-diazabicyclo[5.4.0]undec-7-
ene and 1.94 mL of methyl iodide. After stirring at room
temperature for 2.5 hours, the volatiles were removed,
ethyl acetate added, washed with dilute hydrochloric
25 acid, water, brine, dried and concentrated to afford
2.82g of a pale oil, identified as 2(S)-methyl-3-
(thiomethyl)propionic acid t-butyl ester.

To a solution of 2.82g of 2(S)-methyl-3-(thiomethyl)propionic acid t-butyl ester in 50 mL of acetic acid was added 5.58g of sodium perborate and the mixture heated to 55°C for 17 hours. The reaction was
5 poured into water, extracted with methylene chloride, washed with aqueous sodium bicarbonate, dried and concentrated to afford 2.68g of 2(S)-methyl-3-(methylsulfonyl)propionic acid t-butyl ester as a white solid.

10

To 2.68g of 2(S)-methyl-3-(methylsulfonyl)-propionic acid t-butyl ester was added 20 mL of 4N hydrochloric acid/dioxane and the mixture stirred at room temperature for 19 hours. The solvent was removed under
15 reduced pressure to afford 2.18g of crude product, which was recrystallized from ethyl acetate/hexane to yield 1.44g of 2(S)-methyl-3-(methylsulfonyl)propionic acid as white crystals.

20

Example 12

PART A:

A solution of methyl methacrylate (7.25 g, 72.5 mmol) and phenethyl mercaptan (10.0 g, 72.5 mmol) in 100
25 mL of methanol was cooled in an ice bath and treated with sodium methoxide (100 mg, 1.85 mmol). The solution was stirred under nitrogen for 3 h and then concentrated in vacuo to give an oil that was taken up in ether and washed with 1 N aqueous potassium hydrogen sulfate,
30 saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered and concentrated to give 16.83 g, 97.5% of methyl 2-(R,S)-methyl-4-thia-6-phenyl hexanoate as an oil. TLC on SiO₂ eluting with 20:1 hexane:ethyl acetate (v:v) R_f=0.41. Alternatively, one
35 can use methyl 3-bromo-2-methyl propionate in place of methyl methacrylate.

PART B:

A solution of methyl 2-(R,S)-methyl-4-thia-6-phenyl hexanoate (4.00 g, 16.8 mmol) in 100 mL of dichloromethane was stirred at room temperature and treated
5 portion wise with meta-chloroperoxybenzoic acid (7.38 g, 39.2 mmol) over approximately 40 m. The solution was stirred at room temperature for 16 h and then filtered and the filtrate washed with saturated aqueous sodium
10 bicarbonate, 1N sodium hydroxide, saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated to give 4.50 g, 99% of desired sulfone. The unpurified sulfone was dissolved in 100 mL of tetrahydrofuran and treated with a solution of lithium
15 hydroxide (1.04 g, 24.5 mmol) in 40 mL of water. The solution was stirred at room temperature for 2 m and then concentrated in vacuo. The residue was then acidified with 1N aqueous potassium hydrogen sulfate to pH=1 and then extracted three times with ethyl acetate. The combined
20 ethyl acetate solution was washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered and concentrated to give a white solid. The solid was taken up in boiling ethyl acetate/hexane and allowed to stand undisturbed whereupon white needles formed that were isolated by filtration and air dried to give 3.38 g, 79% of
25 2-(R,S)-methyl-3(β -phenethylsulfonyl)-propionic acid, mp 91-93°C.

PART C:

A solution of 2-(R,S)-methyl-3(β -phenethylsulfonyl)-propionic acid (166.1 mg, 0.65 mmol),
30 N-hydroxybenzotriazole (HOBT) (146.9 mg, 0.97 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (145.8 mg, 0.75 mmol) in 4 mL of anhydrous dimethylformamide (DMF) cooled to 0°C and
35 stirred under nitrogen for 0.5 h. This solution is then treated with a desired sulfonamide isostere and stirred at room temperature for 16 h. The solution is poured

into 30 mL of 60% saturated aqueous sodium bicarbonate solution. The aqueous solution is then decanted from the organic residue. The organic residue is taken up in dichloromethane and washed with 10% aqueous citric acid, brine, dried over anhydrous magnesium sulfate, filtered and concentrated. Flash chromatography of the mixture on silica gel eluting with 1:1 hexane:ethyl acetate can be utilized and will afford the separated diastereomers.

10

Example 13PART A:

A solution of methyl 2-(bromomethyl)-acrylate (26.4 g, 0.148 mol) in 100 mL of methanol was treated with sodium methanesulfinate (15.1 g, 0.148 mol) portion wise over 10 m at room temperature. The solution was then stirred at room temperature for a period of 1.25 h and the solution concentrated in vacuo. The residue was then taken up in water and extracted four times with ethyl acetate. The combined ethyl acetate solution was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, filtered and concentrated to give a white solid, 20.7 g which was taken up in boiling acetone/methyl tert-butyl ether and allowed to stand whereupon crystals of pure methyl 2-(methylsulfonylmethyl) acrylate 18.0 g, 68% formed, mp 65-68 °C.

PART B:

A solution of methyl 2-(methylsulfonylmethyl) acrylate (970 mg, 5.44 mmol) in 15 mL of tetrahydrofuran was treated with a solution of lithium hydroxide (270 mg, 6.4 mmol) in 7 mL of water. The solution was stirred at room temperature for 5 m and then acidified to pH=1 with 1 N aqueous potassium hydrogen sulfate and the solution extracted three times with ethyl acetate. The combined ethyl acetate solution was dried over anhydrous magnesium

sulfate, filtered, and concentrated to give 793 mg, 89% of 2-(methylsulfonylmethyl) acrylic acid, mp 147-149 °C.

PART C:

- 5 A solution of 2-(methylsulfonylmethyl) acrylic acid (700 mg, 4.26 mmol) in 20 mL of methanol was charged into a Fisher-Porter bottle along with 10% palladium on carbon catalyst under a nitrogen atmosphere. The reaction vessel was sealed and flushed five times with
10 nitrogen and then five times with hydrogen. The pressure was maintained at 50 psig for 16 h and then the hydrogen was replaced with nitrogen and the solution filtered through a pad of celite to remove the catalyst and the filtrate concentrated in vacuo to give 682 mg 96% of
15 2-(R,S)-methyl-3-methylsulfonyl propionic acid.

PART D:

- A solution of 2-(R,S)-methyl-3(methylsulfonyl) propionic acid (263.5 mg, 1.585 mmol),
20 N-hydroxybenzotriazole (HOBT) (322.2 mg, 2.13 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (339.1 mg, 1.74 mmol) in 4 mL of anhydrous dimethylformamide (DMF) is cooled to 0°C and stirred under nitrogen for 0.5 h. This solution is then
25 treated with a desired sulfonamide and stirred at room temperature for 16h. The solution is poured into 60 mL of 60% saturated aqueous sodium bicarbonate solution. The aqueous solution is then decanted from the organic residue. The organic residue is taken up in
30 dichloromethane and washed with 10% aqueous citric acid, brine, dried over anhydrous magnesium sulfate, filtered and concentrated to give the desired product.

Example 14Preparation of Sulfone Inhibitors From L-(+)-S-acetyl- β -mercaptoisobutyric Acid

5

PART A:

A round-bottomed flask is charged with the desired sulfamic acid isostere (2.575 mmol), for example, the amine from Example 8, Part C, can be coupled to L-(+)-S-acetyl- β -mercapto butyric acid in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (339.1 mg, 1.74 mmol), in 10 mL of CH₂Cl₂ and is allowed to stir at room temperature for 16 h. The solution is concentrated in vacuo and the residue taken up in ethyl acetate, washed with 1N KHSO₄ sat. aq. NaHCO₃, brine, dried over anhydrous MgSO₄, filtered and concentrated to give an oil which can be purified by radial chromatography on SiO₂ eluting with ethyl acetate to give the pure product.

20

PART B:

A solution of the product of Part A (0.85 mmol) in 10 mL of methanol is treated with anhydrous ammonia for ca. 1 m at 0°C. The solution is stirred at that temperature for 16 h and then concentrated in vacuo to give the desired product that can be used directly in the next step without further purification.

25

PART C:

A solution of the product of Part B (0.841 mmol) in 10 mL of dry toluene under nitrogen is treated in rapid succession with 1,8-diazabicyclo[5.4.0]undec-7-ene, (DBU), (128.1 mg, 0.841 mmol) and iodomethane (119.0 mg, 0.841 mmol). After 0.5 h at room temperature the reaction is diluted with ethyl acetate washed with 1N KHSO₄, sat. aq. NaHCO₃, brine. After the solution is dried over anhydrous MgSO₄, filtered and concentrated

35

in vacuo the desired product is obtained and can be used directly in the next step.

PART D:


- 5 A solution of the product of Part C (0.73 mmol) and sodium perborate (500 mg, 3.25 mmol) in 30 mL of glacial acetic acid is warmed to 55°C for 16 h. The solution is concentrated in vacuo and then the residue is taken up in ethyl acetate, washed with water, sat. aq. NaHCO₃, brine, dried over anhydrous MgSO₄, filtered and concentrated to give the desired product.
- 10

Representative sulfones prepared according to the above general procedures are shown in Table 2.

15

Table 2

20



25

Entry

R

1

CH₃-

2

PhCH₂CH₂-

3

Ph-

General Procedure for Coupling Sulfonyl Alkanoyl
Compounds to Sulfamic Acid Compounds

A mixture of the sulfonyl alkanoyl compound
5 (approximately 1 mmol), N-hydroxybenzotriazole (1.5
mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (EDC) (1.2 mmol) is dissolved in a suitable
solvent such as DMF and allowed to react for about
30 min. at 0°C. The sulfamic acid compounds, for example
10 the amine from example 8, part c, (1.05 mmol) is
dissolved in DMF, added to the above mixture and stirred
at room temperature for a period of time sufficient for
the reaction to take place. The solution is then poured
into saturated aqueous NaHCO₃ and extracted with, for
15 example, ethyl acetate. The extracts are washed, dried,
filtered and concentrated. The resulting material is
then crystallized from a suitable solvent or solvent
mixture such as hexanes and ethyl acetate to produce the
product, or alternatively purified by chromatography.

20

General Procedure for Preparation of Sulfamoyl Chlorides

A. To a solution of 547 mmol of sulfuryl chloride
in 100 mL of anhydrous acetonitrile under a nitrogen
25 atmosphere, was added 136 mmol of amine hydrochloride and
the mixture heated to reflux for twenty-four to forty-
eight hours. The solution was cooled and concentrated in
vacuo to afford a semi-solid. Anhydrous diethyl ether
was added, the solids removed by filtration are the
30 filtrate concentrated to afford the crude sulfamoyl
chloride. This can be used as is, or if desired,
purified by either crystallization or distillation.

B. Preparation of Sulfamoyl Chlorides

Method A:

5 An amino acid ester hydrochloride (1 mmol) is suspended
in a suitable solvent such as hexane, dichloromethane,
toluene and the like, but most preferable acetonitrile.
To the well stirred mixture is added sulfuryl chloride
10 (3 mmol) in a suitable solvent, or neat, dropwise over
several minutes. The reaction is allowed to stir at
zero to reflux temperatures, preferable at reflux, for
1 to 48 hours, preferably for 24 hours. The solvent is
removed and the residue triturated with a suitable
15 solvent, such as hexane, pentane, toluene, but most
preferably diethyl ether. The solvent is decanted and
concentrated. The product may then be utilized as such
or purified by distillation or in the case of solids
recrystallized from appropriate solvents.

20 Method B:

An alpha-hydroxy ester (1 mmol) is dissolved in an
appropriate solvent such as acetonitrile,
dichloromethane, toluene and the like, but most
25 preferable hexane. Chlorosulfonyl isocyanate (1 mmol)
added neat or in a solvent, preferably in hexane, is
added dropwise. The reaction is stirred from zero to
reflux, preferably at reflux, for 5 minutes to several
hours, preferably for 1 hour. The solvent is then
30 removed and the residue used as such, or taken up in an
appropriate solvent, especially dichloromethane, and
filtered to remove any impurities. The product may
then be purified by distillation or in the case of
solids recrystallized from appropriate solvents.


35

C. Preparation of Sulfamates

An amino alcohol as prepared in Example 3 (1 mmol) and a suitable base, such as triethylamine, pyridine, sodium carbonate, and the like, preferably diisopropylethylamine (1 mmol) are dissolved in a suitable solvent such as ether, chloroform, acetonitrile and the like, but preferably dichloromethane. The sulfamoyl chloride from part A or B of Example 4, neat or dissolved in an appropriate solvent, is added to the above solution. The reaction is stirred at zero to reflux temperatures, but preferably at room temperature for 1 to 48 hours. The product can be purified by silica gel chromatography or by an extractive workup followed by recrystallization.

A representative compound prepared according to these general procedures is shown in the following Example.

20

Example 15


Preparation of N-[3-[[[(1,1-dimethylethyl)amino]-
sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-
(phenylmethyl)propyl]-2S-methyl-3-
(methylsulfonyl)propanamide

5

To a solution of 52 mg (0.31 mmol) of 2(S)-methyl-3-(methylsulfonyl) propionic acid and 71 mg (0.46 mmol) N-hydroxybenzotriazole in 2 mL of N,N-dimethylformamide (DMF) at 0°C, was added 65 mg
10 (0.34 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. After stirring at 0°C for one hour, a solution of 104 mg (0.28 mmol) of free amine from Example 8, Part C in 1.5 mL of DMF was added. After two hours at 0°C and sixteen hours at room
15 temperature, the solvent was removed in vacuo, the residue dissolved in ethyl acetate and sequentially washed with saturated aqueous sodium bicarbonate, 5% aqueous citric acid, saturated sodium chloride, dried over anhydrous magnesium sulfate, filtered and
20 concentrated to afford 140 mg of crude product. This was chromatographed on silica gel using 3%-5% isopropanol/methylene chloride to provide 45 mg of the desired product, m/e = 520 (M+H).

25 Utilizing the procedures set forth above, the compounds shown in Tables 3-13 could be prepared. Thus, utilizing the intermediates of Examples 1-10 and coupling such intermediates to the sulfonyl alkanoyl compounds of Examples 11-14 according to the procedure illustrated by
30 Example 15, the compounds shown in Tables 3-16 could be prepared.

TABLE 3



5

Entry No.	R ³	R ⁴	R ⁵
1	CH ₃	n-Butyl	CH ₃
10 2	i-Butyl	CH ₃	C ₆ H ₅
3	i-Butyl	n-Butyl	CH ₃
4	i-Butyl	n-Butyl	H
5	i-Propyl	n-Butyl	H
6	i-Propyl	n-Butyl	CH ₃
15 7	C ₆ H ₅	n-Butyl	H
8	-CH ₂ -	n-Butyl	H
9	-CH ₂ -	n-Butyl	CH ₃
10 10	-CH ₂ -	n-Butyl	H
11		n-Butyl	CH ₃
20 12	i-Butyl	n-Propyl	CH ₃
13	i-Butyl	-CH ₂ CH(CH ₃) ₂	CH ₃
14	(R)-CH(CH ₃)-	n-Butyl	CH ₃
15	CH ₂ -	i-Propyl	CH ₃
16	-CH ₂ -	-CH ₂ CH ₂ CH(CH ₃) ₂	CH ₃
25 17	i-Butyl	-CH ₂ CH ₃	CH ₃
18	i-Butyl	-CH(CH ₃) ₂	CH ₃

TABLE 3 (Cont'd.)








Entry No.	R ³	R ⁴	R ⁵
19	i-Butyl		CH ₃
20	-Butyl		H
21	-CH ₂ - 	-(CH ₂) ₂ CH(CH ₃) ₂	CH ₃
22	(CH ₂) ₂ CH(CH ₃) ₂	-CH(CH ₃) ₂	CH ₃
23	i-Butyl	-CH(CH ₃) ₂	H
24	i-Butyl	-C(CH ₃) ₃	CH ₃
25	i-Butyl	-C(CH ₃) ₃	H
26	-CH ₂ - 	-C(CH ₃) ₃	CH ₃
27	-CH ₂ - 	-C(CH ₃) ₃	H
28	-(CH ₂) ₂ CH(CH ₃) ₂	-C(CH ₃) ₃	H
29	-(CH ₂) ₂ CH(CH ₃) ₂	-C(CH ₃) ₃	CH ₃
30	-CH ₂ C ₆ H ₅	-C(CH ₃) ₃	CH ₃
31	-CH ₂ C ₆ H ₅	-C(CH ₃) ₃	H
32	-(CH ₂) ₂ C ₆ H ₅	-C(CH ₃) ₃	CH ₃
33	-(CH ₂) ₂ C ₆ H ₅	-C(CH ₃) ₃	H
34	n-Butyl	-C(CH ₃) ₃	H
35	n-Pentyl	-C(CH ₃) ₃	CH ₃
36	n-Hexyl	-C(CH ₃) ₃	CH ₃
37	-CH ₂ - 	-C(CH ₃) ₃	CH ₃
38	-CH ₂ C(CH ₃) ₃	-C(CH ₃) ₃	CH ₃
39	-CH ₂ C(CH ₃) ₃	-C(CH ₃) ₃	H
40	-CH ₂ CH ₂ -N 	-C(CH ₃) ₃	H
41	-CH ₂ C ₆ H ₅ OCH ₃ (para)	-C(CH ₃) ₃	H

TABLE 3 (Cont'd.)












Entry No.	R ³	R ⁴	R ⁵
42		-C(CH ₃) ₃	H
43		-C(CH ₃) ₃	H
44	-(CH ₂) ₂ C(CH ₃) ₃	-C(CH ₃) ₃	CH ₃
45	-(CH ₂) ₂ C(CH ₃) ₃	-C(CH ₃) ₃	H
46	-(CH ₂) ₄ OH	-C(CH ₃) ₃	CH ₃
47	-(CH ₂) ₄ OH	-C(CH ₃) ₃	H
48		-C(CH ₃) ₃	H
49		-C(CH ₃) ₃	CH ₃
50	-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅	CH ₃
51	-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅	H
52	-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅	-CH ₂ CH(CH ₃) ₂
53	-CH ₂ Ph	-Ph	H
54		-Ph	H
55		-Ph	H
56		-Ph	H
57		-Ph	H
58		-Ph	H
59	-CH ₂ CH=CH ₂	-Ph	H
60		-Ph	H
61		-Ph	H
62	-CH ₂ CH ₂ Ph	-Ph	H
63	-CH ₂ CH ₂ CH ₂ CH ₂ OH	-Ph	H
64	-CH ₂ CH ₂ N(CH ₃) ₂	-Ph	H

TABLE 3 (Cont'd.)



























Entry	R ³	R ⁴	R ⁵
5 No.			
65	-CH ₂ CH ₂ -N 	-Ph	H
66	-CH ₃	-Ph	H
67	-CH ₂ CH ₂ CH ₂ SCH ₃	-Ph	H
68	-CH ₂ CH ₂ CH ₂ S(O) ₂ CH ₃	-Ph	H
10 69	-CH ₂ CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
70	-CH ₂ CH ₂ CH(CH ₃) ₂	-CH ₂ - 	H
71	-CH ₂ CH ₂ CH(CH ₃) ₂	-CH ₂ CH ₂ CH ₃	H
72	-CH ₂ CH ₂ CH ₂ CH(CH ₃) ₂	-CH ₃	H
73	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
15 74	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
75	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
76	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
77	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
78	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
20 79	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
80	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
81	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
82	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
83	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H
25 84	-CH ₂ CH ₂ CH(CH ₃) ₂	- 	H

TABLE 3 (Cont'd.)

Entry		R ³	R ⁴	R ⁵
5	No.			
	85	-CH ₂ CH ₂ CH(CH ₃) ₂		H
	86	-CH ₂ CH(CH ₃) ₂		H
	87	-CH ₂ CH(CH ₃) ₂		H
	88	-CH ₂ CH(CH ₃) ₂		H
10	89	-CH ₂ CH ₂ CH ₃		H
	90	-CH ₂ CH ₂ CH ₂ CH ₃		H
	91	-CH ₂ CH ₂ CH ₃		H
	92	-CH ₂ CH ₂ CH ₃		H
	93	-CH ₂ CH ₂ CH ₃		H
15	94	-CH ₂ CH ₂ CH ₃		H

74

TABLE 4




5

	Entry	R ¹	R ⁴
	1	CH ₂ SO ₂ CH ₃	t-butyl
10	2	(R) -CH(OH)CH ₃	t-butyl
	3	CH(CH ₃) ₂	t-butyl
	4	(R, S)CH ₂ SOCH ₃	t-butyl
	5	CH ₂ SO ₂ NH ₂	t-butyl
	6	CH ₂ SCH ₃	t-butyl
15	7	CH ₂ CH(CH ₃) ₂	t-butyl
	8	CH ₂ CH ₂ C(O)NH ₂	t-butyl
	9	(S) -CH(OH)CH ₃	t-butyl
	10	-CH ₂ C≡C-H	t-butyl
	11	CH ₃	t-butyl
20	12	CH ₂ CH ₃	t-butyl
	13	C(CH ₃) ₃	t-butyl

75

TABLE 5




5

	Entry	R	R ²
10	1	-OCH ₃	n-Bu
	2	-OCH ₃	cyclohexylmethyl
	3	-NHAC	n-Bu
	4	-NH ₂	n-Bu
	5	-OCH ₃	C ₆ H ₅ CH ₂
15	6	-NHAC	C ₆ H ₅ CH ₂
	7	-NH ₂	C ₆ H ₅ CH ₂
	8	-NHAC	cyclohexylmethyl
	9	-C(CH ₃) ₃	n-Bu
	10	-NH ₂	cyclohexylmethyl
20	11	-C(CH ₃) ₃	C ₆ H ₅ CH ₂
	12	-OCH ₃	2-naphthylmethyl
	13	-NHAC	2-naphthylmethyl
	14	-NH ₂	2-naphthylmethyl
	15	-C(CH ₃) ₃	2-naphthylmethyl
25	16	-OCH ₃	p-F(C ₆ H ₄)CH ₂
	17	-NH ₂	p-F(C ₆ H ₄)CH ₂
	18	-NHAC	p-F(C ₆ H ₄)CH ₂
	19	-C(CH ₃) ₃	p-F(C ₆ H ₄)CH ₂
	20	-CF ₃	C ₆ H ₅ CH ₂
30	21	-CO ₂ CH ₃	C ₆ H ₅ CH ₂
	22	-F	C ₆ H ₅ CH ₂
	23	Cl	C ₆ H ₅ CH ₂

76


TABLE 6



5

Entry	R ³	R ⁴
10	1	-CH ₂ CH(CH ₃) ₂
	2	-CH ₂ CH ₂ CH(CH ₃) ₂
	3	-CH ₂ CH ₂ CH(CH ₃) ₂
	4	-CH ₂ CH ₂ CH(CH ₃) ₂
	5	-CH ₂ CH ₂ CH(CH ₃) ₂
		<div data-bbox="1208 961 1338 991">-C(CH₃)₂</div> <div data-bbox="1208 999 1338 1075"></div> <div data-bbox="1208 1083 1338 1159"></div> <div data-bbox="1208 1167 1338 1243"></div> <div data-bbox="1208 1251 1338 1331"></div>


77

TABLE 7

5

	Entry	R
10	1	CH ₃ -
	2	CH ₃ CH ₂ -
	3	CH ₃ CH ₂ CH ₂ -
	4	PhCH ₂ CH ₂ -
	5	PhCH ₂ -
	6	Ph-
15	7	(CH ₃) ₂ CH-
	8	HOCH ₂ CH ₂ -
	9	$\text{C}_6\text{H}_5\text{CH}_2\text{O}-\overset{\text{O}}{\parallel}\text{CCH}_2$
20	10	$\text{H}_2\text{NCCH}_2-\overset{\text{O}}{\parallel}\text{C}$
	11	
	12	CH ₂ =CH-CH ₂ -

78

Table 8

5

Entry	R ³	-NR ⁴ R ⁵
1	CH ₂ CH(CH ₃) ₂	
2	CH ₂ CH ₂ CH(CH ₃) ₂	
3	-CH ₂ -	
4		
5	-CH(CH ₃) ₂	
6	-CH ₂ -	

15

Example 16

The compounds of the present invention are effective HIV protease inhibitors. Utilizing an enzyme assay as described below, the compounds set forth in the examples herein disclosed inhibited the HIV enzyme. The preferred compounds of the present invention and their calculated IC₅₀ (inhibiting concentration 50%, i.e., the concentration at which the inhibitor compound reduces enzyme activity by 50%) values are shown in Table 17. The enzyme method is described below. The substrate is 2-Ile-Nle-Phe(p-NO₂)-Gln-ArgNH₂. The positive control is MVT-101 (Miller, M. et al, Science, 246, 1149 (1989)). The assay conditions are as follows:

15	Assay buffer:	20 mM sodium phosphate, pH 6.4
		20% glycerol
		1 mM EDTA
		1 mM DTT
20		0.1% CHAPS

The above described substrate is dissolved in DMSO, then diluted 10 fold in assay buffer. Final substrate concentration in the assay is 80 μM.

HIV protease is diluted in the assay buffer to a final enzyme concentration of 12.3 nanomolar, based on a molecular weight of 10,780.

The final concentration of DMSO is 14% and the final concentration of glycerol is 18%. The test compound is dissolved in DMSO and diluted in DMSO to 10x the test concentration; 10 μl of the enzyme preparation is added, the materials mixed and then the mixture is incubated at ambient temperature for 15 minutes. The enzyme reaction is initiated by the addition of 40 μl of

substrate. The increase in fluorescence is monitored at 4 time points (0, 8, 16 and 24 minutes) at ambient temperature. Each assay is carried out in duplicate wells.

5

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

10

TABLE 9

15

Compound of Example No.	IC ₅₀ (nanomolar)
14	140

20

Example 17

25 CEM Cell Assay

The effectiveness of the compounds can also be determined in a CEM cell assay.

30

The HIV inhibition assay method of acutely infected cells is an automated tetrazolium based colorimetric assay essentially that reported by Pawles et al, J. Virol. Methods, 20, 309-321 (1988). Assays can be performed in 96-well tissue culture plates. CEM cells, a CD4⁺ cell line, were grown in RPMI-1640 medium (Gibco) supplemented with a 10% fetal calf serum and were then treated with polybrene (2µg/ml). An 80 µl volume of medium containing 1 x 10⁴ cells is dispensed into each

35

well of the tissue culture plate. To each well is added a 100µl volume of test compound dissolved in tissue culture medium (or medium without test compound as a control) to achieve the desired final concentration and the cells are incubated at 37°C for 1 hour. A frozen culture of HIV-1 is diluted in culture medium to a concentration of 5×10^4 TCID₅₀ per ml (TCID₅₀ = the dose of virus that infects 50% of cells in tissue culture), and a 20µL volume of the virus sample (containing 1000 TCID₅₀ of virus) is added to wells containing test compound and to wells containing only medium (infected control cells). Several wells receive culture medium without virus (uninfected control cells). Likewise, the intrinsic toxicity of the test compound is determined by adding medium without virus to several wells containing test compound. In summary, the tissue culture plates contain the following experiments:

	Virus	Cells	Drug
1.	+	-	-
2.	+	+	-
25 3.	+	-	+
4.	+	+	+

In experiments 2 and 4 the final concentrations of test compounds are 1, 10, 100 and 500 µg/ml. Either azidothymidine (AZT) or dideoxyinosine (ddI) is included as a positive drug control. Test compounds are dissolved in DMSO and diluted into tissue culture medium so that the final DMSO concentration does not exceed 1.5% in any case. DMSO is added to all control wells at an appropriate concentration.

Following the addition of virus, cells are incubated at 37°C in a humidified, 5% CO₂ atmosphere for 7 days. Test compounds could be added on days 0, 2 and 5 if desired. On day 7, post-infection, the cells in each well are resuspended and a 100µl sample of each cell suspension is removed for assay. A 20µL volume of a 5 mg/ml solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is added to each 100µL cell suspension, and the cells are incubated for 4 hours at 27°C in a 5% CO₂ environment. During this incubation, MTT is metabolically reduced by living cells resulting in the production in the cell of a colored formazan product. To each sample is added 100µl of 10% sodium dodecylsulfate in 0.01 N HCl to lyse the cells, and samples are incubated overnight. The absorbance at 590 nm is determined for each sample using a Molecular Devices microplate reader. Absorbance values for each set of wells is compared to assess viral control infection, uninfected control cell response as well as test compound by cytotoxicity and antiviral efficacy.

The biological data shown in Table 10 was obtained from the compounds shown in Table 1C.

Table 10

Biological Data:
Table 1C

Entry:	IC50 or % inhibition	EC50	TD50
A	29% @ 0.1 uM		
B	55% @ 10.0 uM		
C	59% @ 1.0 uM		
D	29% @ 0.1 uM		
E	70 nM	880 nM	7.5 uM
F	22% @ 0.1 uM		

Table 10 (Cont'd)

Biological Data:
Table 1C

5				
	<u>Entry:</u>	<u>IC50 or % inhibition</u>	<u>EC50</u>	<u>TD50</u>
	G	66 nM		
10	H	48% @ 10.0 uM		
	I	1.7 uM		
	J	2.69 uM		
15	K	60% @ 1.0 uM		
	L	38% @ 10.0 uM		
20	M	NT		

The compounds of the present invention are effective antiviral compounds and, in particular, are effective retroviral inhibitors as shown above. Thus, the subject compounds are effective HIV protease inhibitors. It is contemplated that the subject compounds will also inhibit other retroviruses such as other lentiviruses in particular other strains of HIV, e.g. HIV-2, human T-cell leukemia virus, respiratory syncytial virus, simia immunodeficiency virus, feline leukemia virus, feline immuno-deficiency virus, hepadnavirus, cytomegalovirus and picornavirus. Thus, the subject compounds are effective in the treatment and/or prophylaxis of retroviral infections.

Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or nonracemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base. Examples

of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of Formula I with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of Formula I can likewise be obtained by utilizing optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.

20

The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such

35

as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and
5 iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

Examples of acids which may be employed to form
10 pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals,
15 such as sodium, potassium, calcium or magnesium or with organic bases.

Total daily dose administered to a host in single or divided doses may be in amounts, for example, from 0.001
20 to 50 mg/kg body weight daily and more usually 0.01 to 1 mg. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.

The amount of active ingredient that may be
25 combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

The dosage regimen for treating a disease
30 condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological
35 considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular

compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore may deviate from the preferred dosage regimen set forth above.

The compounds of the present invention may be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary
5 temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
10 In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium
15 stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

20 Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents,
25 emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

While the compounds of the invention can be administered as the sole active pharmaceutical agent, they
30 can also be used in combination with one or more immunomodulators, antiviral agents or other antiinfective agents. For example, the compounds of the invention can be administered in combination with AZT, DDI, DDC or with glucosidase inhibitors, such as N-butyl-1-deoxynojirimycin
35 or prodrugs thereof, for the prophylaxis and/or treatment of AIDS. When administered as a combination, the

therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.

5

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.


10

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

15

What Is Claimed Is:

1. A compound represented by the formula



or a pharmaceutically acceptable salt, prodrug or ester thereof wherein:

- 10 R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, aralkoxyalkyl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkyl, aminoalkylcarbonylalkyl, 15 alkylcarbonylalkyl, aryloxyalkylcarbonyl, and aralkoxycarbonylalkyl radicals, aminoalkyl, and mono- and disubstituted aminoalkyl, mono- and disubstituted aminocarbonylalkyl and mono- and disubstituted aminoalkanoylalkyl radicals wherein the substituents are 20 selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl radicals, or wherein said aminoalkyl, aminocarbonylalkyl and aminoalkanoylalkyl radicals are disubstituted, said 25 substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;

- 30 R¹, R²⁰ and R²¹ independently represent hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃), -C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains


- selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine,
- 5 histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, O-alkyl serine, aspartic acid, beta-cyanoalanine and valine side chains;
- R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl
- 10 and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, -NO₂, -CN, -CF₃, -OR⁹ and -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals;
- 15 R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl
- 20 radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along
- 25 with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone and sulfoxide derivatives thereof;
- 30 R⁴ and R⁵ independently represent hydrogen and radicals as defined by R³ or together with a nitrogen atom to which they are bonded form a heterocycloalkyl or a heteroaryl radical;
- 35 R⁶ represents hydrogen and alkyl radicals;

each x independently represents 1 or 2;

t represents either 0, 1 or 2; and

- 5 Y represents O, S and NR¹⁵ wherein R¹⁵ represents hydrogen and radicals as defined for R³.

2. Compound represented by Formula II:



wherein:

- R represents alkyl, alkenyl, alkynyl, cycloalkyl,
 15 hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl,
 heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl,
 aralkyl, heteroalkyl, heteroaralkyl, aminoalkyl,
 aralkoxyalkyl, aminocarbonylalkyl,
 aminoalkylcarbonylalkyl, alkylcarbonylalkyl,
 20 aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl
 radicals;

- R¹, R²⁰ and R²¹ independently represent hydrogen,
 -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂, -CH₂C(O)NHCH₃,
 25 -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃), -C(CH₃)₂(S[O]CH₃),
 -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl
 and cycloalkyl radicals, and amino acid side chains
 selected from asparagine, S-methyl cysteine and
 methionine and the sulfoxide (SO) and sulfone (SO₂)
 30 derivatives thereof, isoleucine, allo-isoleucine,
 alanine, leucine, tert-leucine, phenylalanine, ornithine,
 histidine, norleucine, glutamine, threonine, glycine,

allo-threonine, serine, O-methyl serine, aspartic acid, beta-cyanoalanine and valine side chains;

R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl
5 and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, -NO₂, -C≡N, CF₃, -OR⁹, -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals;

10 R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl
15 radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along
20 with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone and sulfoxide derivatives thereof;

25 R⁴ and R⁵ independently represent hydrogen and radicals as defined by R³, or together with the nitrogen atom to which they are bonded represent heterocycloalkyl and heteroaryl radicals; and

30 t represents 0 or 1.

3. Compound of Claim 2 wherein R represents alkyl, aryl and aralkyl radicals.

35 4. Compound of Claim 2 wherein R represents methyl and phenethyl radicals.

5. Compound of Claim 2 wherein R^1 , R^{20} and R^{21} independently represent hydrogen $\text{CH}_2\text{C}(\text{O})\text{NHCH}_3$, $\text{C}(\text{CH}_3)_2(\text{SCH}_3)$, $\text{C}(\text{CH}_3)_2(\text{S}[\text{O}]\text{CH}_3)$, $\text{C}(\text{CH}_3)_2(\text{S}[\text{O}]_2\text{CH}_3)$, alkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, threonine, allo-threonine, isoleucine, tert-leucine, S-methyl cysteine and methionine and the sulfone and sulfoxide derivatives thereof, alanine, and allo-isoleucine.

6. Compound of Claim 2 wherein R^1 , R^{20} and R^{21} independently represent hydrogen, $\text{CH}_2\text{C}(\text{O})\text{NHCH}_3$, $\text{C}(\text{CH}_3)_2(\text{SCH}_3)$, $\text{C}(\text{CH}_3)_2(\text{S}[\text{O}]\text{CH}_3)$, $\text{C}(\text{CH}_3)_2(\text{S}[\text{O}]_2\text{CH}_3)$, methyl, propargyl, t-butyl, isopropyl and sec-butyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, S-methyl cysteine, allo-isoleucine, iso-leucine, and beta-cyano alanine side chains.

7. Compound of Claim 2 wherein R^1 , R^{20} and R^{21} independently represent hydrogen and methyl, ethyl, propargyl, t-butyl, isopropyl and sec-butyl radicals.

8. Compound of Claim 2 wherein R^2 represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula $-\text{OR}^9$ and $-\text{SR}^9$ wherein R^9 represents hydrogen and alkyl radicals.

9. Compound of Claim 2 wherein R^2 represents alkyl, cycloalkylalkyl and aralkyl radicals.

10. Compound of Claim 2 wherein R^2 represents $\text{CH}_3\text{SCH}_2\text{CH}_2-$, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals.

11. Compound of Claim 2 wherein R³ represents alkyl, haloalkyl, alkenyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl and heteroaralkyl radicals.

5

12. Compound of Claim 2 wherein R⁵ is hydrogen and R³ represents alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl radicals.

10

13. Compound of Claim 2 wherein R³ represents alkyl, heterocycloalkyl and heterocycloalkylalkyl radicals.

15

14. Compound of Claim 2 wherein R³ represents isobutyl, n-propyl, isopropyl, n-butyl, isoamyl, cyclohexyl, cyclohexylmethyl, benzyl and pyridylmethyl radicals.

20

15. Compound of Claim 2 wherein R⁵ is hydrogen, R³ is a isobutyl or isoamyl radical and R⁴ is a tertiary-butyl radical.

25

16. Compound of Claim 2 wherein R⁵ is hydrogen, R³ is a cyclohexyl or cyclohexylmethyl radical and R⁴ is a tertiary-butyl radical.

30

17. Compound of Claim 2 wherein R⁴ and R⁵ independently represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals.

35

18. Compound of Claim 2 wherein R⁴ and R⁵ independently represent hydrogen, alkyl and aryl radicals.

19. Compound of Claim 2 wherein R⁴ and R⁵
independently represent hydrogen, methyl, ethyl,
isopropyl, propyl, n-butyl, t-butyl, 1,1-dimethylpropyl,
5 cyclohexyl and phenyl radicals.

20. Compound of Claim 2 wherein R⁴ and R⁵
together with the nitrogen atom to which they are bonded
form a heterocyloalkyl or heteroaryl radical.
10

21. Compound of Claim 2 wherein R⁴ and R⁵
together with the nitrogen atom to which they are bonded
form a heterocycloalkyl or heteroaryl radical having from
4 to 8 ring members.
15

22. Compound of Claim 2 wherein R⁴ and R⁵
together with the nitrogen atom to which they are bonded
form a pyrrolidinyl, piperidinyl, morpholinyl,
piperazinyl or N-alkylpiperazinyl radical.
20

23. A pharmaceutical composition comprising a
compound of Claim 1 and a pharmaceutically acceptable
carrier.

24. A pharmaceutical composition comprising a
compound of Claim 2 and a pharmaceutically acceptable
carrier.
25

25. Method of inhibiting a retroviral protease
30 comprising administering a protease inhibiting amount of
a composition of Claim 23.

26. Method of Claim 25 wherein the retroviral
protease is HIV protease.
35

27. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 23.

5 28. Method of Claim 27 wherein the retroviral infection is an HIV infection.

 29. Method for treating AIDS comprising administering an effective amount of a composition of
10 Claim 23.

 30. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of
15 a composition of Claim 24.


 31. Method of Claim 30 wherein the retroviral protease is HIV protease.

 32. Method of treating a retroviral infection
20 comprising administering an effective amount of a composition of Claim 24.

 33. Method of Claim 30 wherein the retroviral infection is an HIV infection.
25

 34. Method for treating AIDS comprising administering an effective amount of a composition of
Claim 24.

30 35. Compound represented by Formula III:



wherein:

R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, aralkoxyalkyl, aminoalkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals;

10

R¹, R²⁰ and R²¹ independently represent hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃), -C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, aspartic acid, beta-cyano alanine and valine side chains;

R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, -NO₂, -C≡N, CF₃, -OR⁹, -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals;

R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,

heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a
5 heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone and sulfoxide derivatives thereof; and

R⁴ and R⁵ independently represent hydrogen and radicals
10 as defined for R³ or together with a nitrogen atom to which they are bonded form a heterocycloalkyl or a heteroaryl radical.

36. Compound of Claim 35 wherein R represents
15 alkyl, aryl and aralkyl radicals.

37. Compound of Claim 35 wherein R represents methyl and phenethyl.

20 38. Compound of Claim 35 wherein R¹, R²⁰ and R²¹ independently represent hydrogen, CH₂C(O)NHCH₃, C(CH₃)₂(SCH₃), C(CH₃)₂(S[O]CH₃), C(CH₃)₂(S[C]CH₃), alkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from the group consisting of
25 asparagine, valine, threonine, allo-threonine, isoleucine, tert-leucine, S-methyl cysteine and methionine and the sulfone and sulfoxide derivatives thereof, alanine, and allo-isoleucine.

30 39. Compound of Claim 35 wherein R¹, R²⁰ and R²¹ independently represent hydrogen CH₂C(O)NHCH₃, C(CH₃)₂(SCH₃), C(CH₃)₂(S[O]CH₃), C(CH₃)₂(S[C]CH₃), methyl, ethyl, propargyl, t-butyl, isopropyl and sec-butyl radicals, and amino acid side chains selected from the
35 group consisting of asparagine, valine, S-methyl

cysteine, allo-iso-leucine, iso-leucine, and beta-cyano alanine side chains.

40. Compound of Claim 35 wherein R¹, R²⁰ and R²¹
5 independently represent hydrogen, methyl, ethyl, propargyl, t-butyl, isopropyl and sec-butyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, S-methyl cysteine, methionine, allo-iso-leucine, iso-leucine, threonine, serine, aspartic acid,
10 beta-cyano alanine, and allo-threonine side chains.

41. Compound of Claim 35 wherein R¹, R²⁰ and R²¹ independently represent hydrogen and methyl, ethyl, propargyl, t-butyl, isopropyl and sec-butyl radicals.
15

42. Compound of Claim 35 wherein R² represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula -OR⁹ and -SR⁹
20 wherein R⁹ represents hydrogen and alkyl radicals.

43. Compound of Claim 35 wherein R² represents alkyl, cycloalkylalkyl and aralkyl radicals.

44. Compound of Claim 35 wherein R² represents CH₃SCH₂CH₂-, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals.
25

45. Compound of Claim 35 wherein R² represents benzyl, 4-fluorobenzyl, and 2-naphthylmethyl radicals.
30

46. Compound of Claim 35 wherein R³ independently represents alkyl, haloalkyl, alkenyl, alkynyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl and heteroaralkyl radicals.
35

47. Compound of Claim 35 wherein R³ represents
alkyl, cycloalkyl, cycloalkylalkyl, aralkyl,
heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl
5 radicals.

48. Compound of Claim 35 wherein R³ represents
isobutyl, n-propyl, isopropyl, n-butyl, isoamyl,
cyclohexyl, cyclohexylmethyl, benzyl and pyridylmethyl
10 radicals.

49. Compound of Claim 35 wherein R⁵ is
hydrogen and R³ and R⁴ independently represent alkyl,
heterocycloalkyl and heterocycloalkylalkyl radicals.
15

50. Compound of Claim 35 wherein R⁵ is
hydrogen, R³ is a isobutyl or isoamyl radical and R⁴ is a
tertiary-butyl radical.
20

51. Compound of Claim 35 wherein R⁴ and R⁵
independently represent hydrogen, alkyl, cycloalkyl,
cycloalkylalkyl, aryl, heteroaryl, aralkyl,
heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl
25 radicals.

52. Compound of Claim 35 wherein R⁴ and R⁵
independently represent hydrogen, alkyl and aryl
radicals.
30

53. Compound of Claim 35 wherein R⁴ and R⁵
independently represent hydrogen, methyl, ethyl, propyl,
isopropyl, n-butyl, t-butyl, 1,1-dimethylpropyl,
cyclohexyl and phenyl radicals.
35

54. Compound of Claim 35 wherein R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a heterocycloalkyl or heteroaryl radical.

5 55. Compound of Claim 35 wherein R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a heterocycloalkyl or heteroaryl radical having from 4 to 8 ring members.

10 56. Compound of Claim 35 wherein R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl or N'-alkylpiperazinyl radical.

15 57. A pharmaceutical composition comprising a compound of Claim 35 and a pharmaceutically acceptable carrier.

20 58. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 57.


25 59. Method of Claim 58 wherein the retroviral protease is HIV protease.

60. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 57.

30 61. Method of Claim 60 wherein the retroviral infection is an HIV infection.

35 62. Method for treating AIDS comprising administering an effective amount of a composition of Claim 57.

63. Compound represented by by Formula IV:



wherein:

5

R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, aralkoxyalkyl, aminoalkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals;

15 R¹, R²⁰ and R²¹ independently represent hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃), -C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, aspartic acid, beta-cyano alanine and valine side chains;

25 R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, -NO₂, -C≡N, CF₃, -OR⁹ and -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals;

R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkyl and the sulfone and sulfoxide derivatives thereof; and

R⁴ and R⁵ independently represent hydrogen and radicals as defined by R³, or together with the nitrogen atom to which they are bonded represent heterocycloalkyl and heteroaryl radicals.

64. Compound of Claim 63 wherein R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals.

65. Compound of Claim 63 wherein R represents alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, alkoxyalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, aminocarbonylalkyl, aminoalkylcarbonylalkyl, alkylcarbonylalkyl, aryloxyalkylcarbonylalkyl and aralkoxycarbonylalkyl radicals.

66. Compound of Claim 63 wherein R represents methyl and phenethyl radicals.

5 67. Compound of Claim 63 wherein R¹, R²⁰ and R²¹ independently represent hydrogen and alkyl radicals having from 1 to about 4 carbon atoms, alkenyl, alkynyl and aralkyl radicals and radicals selected from
10 -CH₂SO₂NH₂, -CO₂CH₃, -CONHCH₃, -CON(CH₃)₂, -CH₂C(O)NHCH₃,
 -CH₂C(O)N(CH₃)₂, -CONH₂, -C(CH₃)₂(SCH₃),
 -C(CH₃)₂(S[O]CH₃) and -C(CH₃)₂(S[O]₂CH₃).

15 68. Compound of Claim 63 wherein R¹, R²⁰ and R²¹ independently represent hydrogen, methyl, ethyl, isopropyl, propargyl and tertiary butyl radicals.

 69. Compound of Claim 63 wherein R²⁰ and R²¹ are both hydrogen and R¹ is methyl.

20 70. Compound of Claim 63 wherein R¹ and R²⁰ are both hydrogen and R²¹ is methyl.

 71. Compound of Claim 63 wherein R¹ is hydrogen and R²⁰ and R²¹ are both methyl.
25

 72. Compound of Claim 63 wherein R²¹ is hydrogen and R¹ and R²⁰ together with the carbon atoms to which they are attached form a three to six-membered cycloalkyl radical.
30

 73. Compound of Claim 63 wherein R¹, R²⁰ and R²¹ are each methyl.

 74. Compound of Claim 63 wherein R¹ is methyl,
35 one of R²⁰ and R²¹ is methyl and the other is hydrogen.

75. Compound of Claim 63 wherein R² represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula -OR⁹ and -SR⁹ wherein R⁹ represents hydrogen and alkyl radicals.

76. Compound of Claim 63 wherein R² represents alkyl, cycloalkylalkyl and aralkyl radicals.

77. Compound of Claim 63 wherein R² represents aralkyl radicals.

78. Compound of Claim 63 wherein R³ independently represents alkyl, haloalkyl, alkenyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl and heteroaralkyl radicals.

79. Compound of Claim 63 wherein R³ represents alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl radicals.

80. Compound of Claim 63 wherein R³ represents alkyl, heterocycloalkyl and heterocycloalkylalkyl radicals.

81. Compound of Claim 63 wherein R³ represents isobutyl, n-propyl, isopropyl, n-butyl, isoamyl, cyclohexyl, cyclohexylmethyl, benzyl and pyridylmethyl radicals.

82. Compound of Claim 63 wherein R⁵ is hydrogen, R³ is a isobutyl or isoamyl radical and R⁴ is a tertiary-butyl radical.

83. Compound of Claim 63 wherein R⁵ is hydrogen, R³ is a cyclohexyl or cyclohexylmethyl radical and R⁴ is a tertiary-butyl radical.

5 84. Compound of Claim 63 wherein R⁴ and R⁵ independently represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals.

10

85. Compound of Claim 63 wherein R⁴ and R⁵ independently represent hydrogen, alkyl and aryl radicals.

15

86. Compound of Claim 63 wherein R⁴ and R⁵ independently represent hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, 1,1-dimethylpropyl, cyclohexyl and phenyl radicals.

20

87. Compound of Claim 63 wherein R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a heterocycloalkyl or heteroaryl radical.

25 88. Compound of Claim 63 wherein R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a heterocycloalkyl or heteroaryl radical having from 4 to 8 ring members.

30 89. Compound of Claim 63 wherein R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl or N'-alkylpiperazinyl radical.

35 90. A pharmaceutical composition comprising a compound of Claim 63 and a pharmaceutically acceptable carrier.

91. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 90.

5

92. Method of Claim 91 wherein the retroviral protease is HIV protease.

93. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 90.

10

94. Method of Claim 93 wherein the retroviral infection is an HIV infection.

15

95. Method for treating AIDS comprising administering an effective amount of a composition of Claim 90.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/10461

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07C317/44 A61K31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,92 08701 (MONSANTO et al.) 29 May 1992 see pages 3-6; pages 78-85; claims 1,78, 117,118 -----	1,2,35, 63

☐ Further documents are listed in the continuation of box C.


Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
 E earlier document but published on or after the international filing date
 L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 O document referring to an oral disclosure, use, exhibition or other means
 P document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 & document member of the same patent family

Date of the actual completion of the international search

3 February 1994

Date of mailing of the international search report

14.02.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/ 10461

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 25-34, 58-62, 91-95 are directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The terms "prodrug" and "ester" are imprecise and it is not possible to determine which compounds are meant by them. Since there are no examples of prodrugs or esters of compounds of formula (I) in the description, they were not included in the search. (Claim 1 searched incompletely).
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 93/10461

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9208701	29-05-92	AU-A- 9053191	11-06-92
		AU-A- 9085191	11-06-92
		AU-A- 9092591	11-06-92
		AU-A- 9125191	11-06-92
		AU-A- 9133291	11-06-92
		CA-A- 2096407	20-05-92
		CA-A- 2096409	20-05-92
		CA-A- 2096525	20-05-92
		CA-A- 2096528	20-05-92
		EP-A- 0558603	08-09-93
		EP-A- 0554400	11-08-93
		EP-A- 0558630	08-09-93
		EP-A- 0558657	08-09-93
		EP-A- 0558673	08-09-93
		WO-A- 9208698	29-05-92
		WO-A- 9208699	29-05-92
		WO-A- 9208700	29-05-92
		WO-A- 9208688	29-05-92
